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Abstract
DNA mutation, epigenetic alteration, and gene expression are three major
molecular components that distinguish cancer from normal cells. Although it
is widely accepted that epigenetic modifications can greatly affect the expres-
sion of the target genes, because of the complex combinations of epigenetic
marks, together with the interactions between multiple non-coding regula-
tory elements, measuring the epigenetic effects on gene expression is not an
easy task. Nevertheless, it is estimated that epigenetic modifications have a
greater effect than DNA mutations on tumorigenesis. In addition, epigenetic
alterations are the initiating factor in some chromosome abnormalities and
aberrant gene expression, making the study of epigenetic alterations a cen-
tral aspect in understanding the underlying mechanisms in cancer and cell
development.
The aim of this thesis is to conduct qualitative and quantitative analysis
on differential epigenetic modifications. To this end, a variety of existing
approaches were applied in the ChIP-Seq analyses of six histone marks on
glioblastoma data from four distinct subtypes. The results depict a com-
prehensive landscape of active and poised regulatory elements specific to
glioblastoma subtypes, which describe the different aspects of tumor progres-
sion. However, the descriptive model of multiple histone marks (ChromHMM
and peak calls) was also shown to be prone to various biases and artifacts.
Moreover, some models also neglect the quantitative information of ChIP-
Seq data, making it inadequate in addressing the magnitude of epigenetic
modifications in gene expression levels. Therefore, in the second part of
my work, I designed an integrated, network based approach, in which I in-
tegrated two levels of epigenetic information: the signal intensities of each
epigenetic mark, and the relationships between promoters and distal regu-
latory elements known as enhancers. Applying this approach to a variety
of test cases, it predicts a number of candidate genes with significant epige-
netic alterations, and comprehensive benchmarking validated these findings
in cancer and stem cell developments.
In summary, as increasing amounts of epigenetic data become available,
the computational approaches employed in this study would be highly rel-
evant in both comparative and integrative analysis on the epigenetic land-
scape. The discovery of novel epigenetic targets in cancers, not only unfolds
the fundamental mechanisms in tumorigenesis and development, but also
serves as an emerging resource for molecular diagnosis and treatment.
Zusammenfassung
DNA-Mutationen, epigenetische Vera¨nderungen und Genexpression sind drei
wichtige molekulare Eigenschaften, die Krebszellen von normalen Zellen un-
terscheiden. Es ist allgemein anerkannt, dass epigenetische Vera¨nderungen
die Expression der Zielgene stark beeinflussen ko¨nnen. Aufgrund der kom-
plexen Kombinationen von epigenetischen Markierungen und der Wechsel-
wirkungen zwischen mehreren nicht-kodierenden regulatorischen Elementen
bleibt die Bestimmung der epigenetischen Effekte auf Genexpression eine
Herausforderung. Es wird angenommen, dass epigenetische Vera¨nderungen
eine gro¨ßere Auswirkung als DNA-Mutationen auf die Tumorgenese haben.
Daru¨ber hinaus liegen bei Chromosomenanomalien und anomaler Genex-
pression oft epigenetische Alterationen zugrunde, was die Untersuchung von
epigenetischen Mechanismen zu einer zentralen Frage fu¨r das Versa¨ndnis der
Krebs- und Zellentwicklung macht. Ziel dieser Studie ist es, qualitative und
quantitative Untersuchungen zu differentiellen epigenetischen Modifikatio-
nen durchzufu¨hren. Zu diesem Zweck wurde eine Vielzahl von existieren-
den Ansa¨tzen in den ChIP-Seq-Analysen von sechs Histonmarkierungen von
Glioblastomdaten aus vier verschiedenen Subtypen angewendet. Die Ergeb-
nisse zeigen eine umfassende Landschaft aktiver und ruhender regulatorischer
Elemente, die spezifisch fu¨r bestimmte Glioblastom-Subtypen sind. Die Mod-
elle fu¨r Histonmarkierungen (ChromHMM- und Peak-Calls) erwiesen sich
jedoch in dieser Studie ebenfalls als anfa¨llig fu¨r Verzerrungen und Arte-
fakte. Daru¨ber hinaus vernachla¨ssigt das ChromHMM-Modell auch die quan-
titative Information von ChIP-Seq-Daten und macht es somit ungeeignet,
das Ausmaß epigenetischer Modifikationen in den Genexpressionsniveaus zu
beru¨cksichtigen. Aus diesem Grund habe ich im zweiten Teil meiner Arbeit
ein generisches Modell fu¨r integrative Untersuchungen erstellt. Mit diesem
Modell ko¨nnen zwei Ebene epigenetischer Informationen, na¨mlich die die
Signalintensita¨ten jeder Histonmarkierung und die Zusammenha¨nge von En-
hancern und Promotoren beru¨cksichtigt werden. Mein Ansatz sagt eine Reihe
von Kandidaten mit signifikanten epigenetischen Vera¨nderungen voraus, und
in einem umfassenden Benchmarking mit einer Vielzahl von epigenetischen
Datensa¨tzen konnten diese Ergebnisse in Krebs- und Stammzellentwicklun-
gen bioinformatisch validiert werden. Die Entdeckung neuartiger epigenetis-
cher Targets bei Krebserkrankungen beleuchtet nicht nur die grundlegenden
Mechanismen der Tumorgenese und -entwicklung, sondern dient auch als
Quelle fu¨r die molekulare Diagnose und Behandlung.
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Chapter 1
Introduction
1.1 General concepts in epigenetics regula-
tion
Eukaryotes have a much more complex chromosomal structure than prokary-
otes, which offers more layers of transcriptional regulation. In particular, the
non-coding genome size in eukaryotes is orders of magnitude larger that in
prokaryotes, suggesting that the complexities of the transcriptional regula-
tion, rather than the number of genes, relate to the organismal complexity.
Epigenetics is one of the mechanisms which allows a cell to alter transcription
without changing the DNA sequences, and is usually reversible [1]. This is
beneficial by enabling the cell to quickly adapt to the needs of development
and rapid changes of the environment. But abnormal epigenetic modifi-
cations may also cause persistent activating of cell cycle control genes or
deactivating of DNA repair genes and result in permanent growth of the cell,
and in the end lead to cancer. Here I will explain from the 4W (what, where,
when, who) aspects of epigenetic regulation which compose the fundamentals
of this study.
1.1.1 What are the components in epigenetic regula-
tion?
In this section, I will describe the main types of epigenetic modifications,
leaving the description of the molecular actors of these changes to section
(1.1.4).
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DNA methylation
DNA methylation transforms cytosine into 5-methylcytosine in CpG din-
ucleotides. This transformation occurs through the action of the DNA-
methyltransferase enzymes, namely Dnmt1, Dnmt3a and Dnmt3b. The first
enzyme is responsible for DNA methylation maintenance in replication, while
the latter two as responsible for de novo methylation of unmethylated DNA.
Many genes are transcriptionally repressed by CpG methylation at their
regulatory domains [2]. Global hypomethylation is a common feature in car-
cinogenesis [3], e.g. colorectal [4] and ovarian [5] cancer. On the other hand,
transcription of many tumor suppressor genes are inhibited by hypermethy-
lation [6], affecting many pathways such as apoptosis (DAPK), cell cycle
(p16), cell adherence (CDH1, CDH13), DNA repair (hMLH1, MGMT), and
detoxification (GSTP1) etc. [7]. As an example, ERα gene was progressively
hypermethylated while global DNA became hypomethylated during colorec-
tal cancer development [8].
DNA hypermethylation in the gene bodies, on the contrary, is often as-
sociated with high transcription [9, 10], and is most frequently observed in
housekeeping genes [11]. The gene body methylation can recruit spliceoso-
mal proteins [12] and is probably related to regulation of alternative splic-
ing [12–14].
Histone modification
The core histone proteins H2A, H2B, H3 and H4 each form dimers and
combine into an octameric structure together with the linker H1 protein.
This structure is wrapped by a ∼ 147 bp sequence of DNA. This unit is
called nucleosome, which constitutes a basic component in chromatin.
Covalent modifications on the residues of the histone proteins affect the
accessibility and activity of the chromatin DNA, by modifying the chemical
and physical properties of the protein-DNA interaction. Histone methyla-
tion and acetylation were found more than 40 years ago [15]. Later, mod-
ifications occurring at the lysine, serine, threonine and arginine residues
of histone proteins, and a variety of modifications including methylation,
acetylation, phosphorylation, citrullination, ubiquitination, SUMOylation
and ADP-ribosylation were discovered (Fig. 1.1).
Histone proteins are very conserved across mammals, and their mutations
are associated with several cancers, such as diffuse intrinsic pontine glioma
(DIPG) [16] and chondroblastoma [17]. Dysregulation of histone modifying
enzymes can lead to oncogenesis, making them potential targets for cancer
drugs.
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Figure 1.1: Histone modifications and organization of nucleosome. Methyla-
tion (Me), acetylation (Ac), ubiquitination (Ub), and phosphorylation (Ph)
mostly occur at the N-terminal tail of the histones. Adapted from Epigenet-
ics. 2012;7(8):823-40 [18].
Chromosomal conformation changes
Chromosome has a highly organized three-dimensional architecture, arrang-
ing distal regulatory elements in spatial vicinity of their target gene pro-
moters. Chromosome condensation changes have been well characterized
throughout the various stages of cell cycle. Recently, mounting evidences
suggest that conformation changes are also accompanied with cancer pro-
gression, cause formation of aberrant chromosomal loops [19], and lead to
homologous recombination [20] and probably gene fusion, loss of imprint-
ing [21], or activation of oncogene transcription [22]. A few mediators, such
as ERG overexpression, are known to induce global chromatin conforma-
tion reorganization in prostate cancer [23] and breast cancer [24] cell lines.
The rearrangement of chromosomal conformation results spatial proximity
of ERα binding loci, and promote cancer proliferation [24]. Therefore, pro-
found knowledge of chromatin conformation changes is needed in further
understanding cancer pathology.
Topologically associating domain (TAD) are defined based on chromo-
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some conformation, in which genomic loci within TAD have remarkable
higher contact probabilities. Cohesin and CTCF co-localize at TAD bound-
aries that insulate chromatin contacts from outside of the TAD [25].
1.1.2 Where do epigenetic modifications take place?
Promoter
The gene promoter is a genomic region at which the transcription of the
gene is initiated. The eukaryotic core promoter contains a RNA polymerase
binding site located at ∼ 34bp upstream of the transcription start site (TSS)
[26,27], whereas specific transcription factor binding sites are located ∼ 250
bp upstream of the TSS. Often, the promoter definition is extended to up to
±2kb around the TSS that may contain additional regulatory sequences [28].
In this study, I will generally adopt this extended definition.
It is estimated that 60%-70% of human gene promoters harbor CpG
islands (CGI) [29, 30]. The CpGs in these CGIs are predominantly non-
methylated [31]. However, in certain conditions (for example certain cancer
such as glioblastoma), these CGIs can be hypermethylated, which results in
chromatin compaction and leads to transcriptional repression [2]. In addition
to repression due to DNA methylation, these CGIs can also be repressed via
polycomb-mediated repression [31]. This alternative mechanism of repression
leads to the trimethylation of lysine 27 on histone H3 via the action of the
enzyme EZH2, resulting in a closed chromatin conformation.
Actively transcribed promoters show histone H3 lysine 4 trimethylation
(H3K4me3), which is recognized by the plant homeodomain (PHD) finger
of the TFIID subunit TAF3 [32], wherein H3K9ac and H3K14ac enhanced
TFIID interaction [33]. H3K4me3 also recruits the nucleosome remodeling
factor (NURF) [34] and pre-mRNA splicing protein CHD1 [35] to facilitate
transcription elongation and splicing. Recently, the broadness of H3K4me3
was also found to play a role in the transcription activity of promoters [36].
Histone H3 acetylation at lysine 27 (H3K27ac) is enriched at the pro-
moters of transcriptionally active genes [37]. As opposed to H3K27ac, H3
trimethylation at lysine 27 (H3K27me3) at the promoters inhibit transcrip-
tion. Co-occurrences of H3K4me3 and H3K27me3, two modifications with
opposing effects, are often observed in cultured embryonic stem cells [38–40]
and are termed as ”bivalent domain”. The bivalent configuration reduces
transcription activity, yet allows timely activation upon differentiation sig-
nals [39].
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Enhancer
Enhancers are short cis-elements that interact with promoter through chro-
mosomal loops to increase gene transcription [41,42]. Most of the enhancers
are located within ±1 Mb of the transcription start site (TSS) of their target
genes [43], including intergenic but also intronic regions [44]. Enhancers can
be bound by specific transcription factors which either activate or repress
the binding of general transcription factors (GTFs) and RNA polymerase
II (RNAPII) on promoters [45, 46]. The specific combination, ordering and
spacing of the binding sites are believed to play an important role for the
precise activity of these regulatory elements. The DNA sequences of en-
hancer, as opposed to promoters, show poor conservation across species [47]
and tissues [48].
Enhancer activity in time and across conditions and tissues is regulated
through the epigenetic modifications, including H3K27ac [49] and H3K4me1
[50, 51]. In particular, cell type specificity of enhancers is unveiled from the
unique H3K4me1 patterns in different mammalian cells [51]. Other markers,
such as the presence of DNase I hypersensitive sites [52] or binding of the
transcriptional co-activator p300 [53] are used to identify enhancers. Similar
to promoters, enhancers marked with H3K27ac are termed active [54], and
enhancers with H3K27me3 are bivalent [55]. Recent evidence suggests that
many enhancers are led to the transcription of non-coding RNAs (eRNA) [56],
which can be used as another mark of enhancer activity. Finally, numerous
recent studies have shown that enhancers are often clustered together in
broader domains to form ”super-enhancer”, resulting in much higher ac-
tivities of RNAPII binding and eRNA transcription than individual en-
hancers [57, 58]. In embryonic stem cells, super-enhancers are regulated by
a small number of genes so called ”master regulator”. Super-enhancers are
also found in other cell types, where they play a major role the control of
cell identity and regulation of cell type-specific genes [59].
Insulator
Insulators are another type of cis-regulatory elements, which are rich in re-
peated sequences such as CCCTC. Insulators are often found to be bound by
the transcriptional repressor CTCF. Together with cohesin, they form a com-
plex at the boundaries of topologically-associated domain (TAD). Alterations
in their sequences and aberrant expression or dysfunction of CTCF may drive
cancer, by altering the TAD structure and enabling the aberrant regulation
of oncogenes by distant enhancers. However, other elements are also needed
for TAD formation, such as TFIIIC [60]. Depending on the type of these ad-
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ditional proteins, the complex can have three regulatory activities: (1) isolat-
ing the active chromatin from the repressive chromatin [61], in which USF1
complex form a barrier between the euchromatin and heterochromatin [62].
(2) blocking enhancer from interacting with promoter [63]. (3) promoting
enhancer-promoter interactions, which CTCF forms TAF3/CTCF/cohesin
complex at the core promoter region [64].
1.1.3 When are epigenetic modifications altered?
Environmental exposures
Several environmental exposures, such as carcinogens, infections, nutrition
can affect epigenome modifiers, resulting in epigenetic dysregulation in a
variety of cells, and ultimately increasing the risk of carcinogenesis [65,66].
Environmental contaminants may contain both genotoxic and non-genotoxic
agents, such as pirinixic acid (WY-14643) [67], trichloroacetic acid and dichloroacetic
acid [68], which cause global DNA hypomethylation. Metals, for instance,
nickel (Ni), arsenic (As), lead (Pd), chromium (Cr), cadmium (Cd), have
been reported to affect both DNA methylation (Ni [69,70], As [71], Pd [72,73],
Cr [74, 75], Cd [76, 77]) and histone modification (Ni [78–82], As [83–87],
Pb [73], Cr [88,89]). In addition, benzene exposure plays a role in both acute
myeloid leukemia (AML) [90] and chronic myeloid leukemia (CML) [91] via
both hypomethylation and hypermethylation [92].
Bacteria, such as Helicobacter pylori, can affect the human epigenome in
two ways: either by inducing global hypomethylation [93, 94], or promoting
mutagenesis with mutagen like N-methyl-N-nitrosourea [95]. Viruses, such
as Epstein–Barr virus (EBV), mediate via tumor supressor BIM [96] and
PRDM1 [97] silencing through hypermethylation in EBV-positive Burkitt’s
lymphoma. Similarly, hepatitis B viruses (HBV) has been found to induce hy-
permethylation of several genes (RASSF1A, GSTP1, CHRNA3, and DOK1)
in hepatocellular carcinoma (HCC) [98]. In addition, human papillomavirus
(HPV) infection is associated with promoter hypermethylation of a variety of
tumor suppressor genes, such as p16, CDH1, RARβ, MGMT, DAPK, DCC,
GALR1, and GALR2 [99–101] in head and neck squamous cell carcinoma
(HNSCC). Mechanisms behind these aberrant DNA methylation patterns
may be attributed to overexpression of DNA methyltransferase (DNMT) dur-
ing viral infection [102].
Nutrition has also been shown to impact the epigenome. Maternal diet
can impact the baby’s epigenetic status in in utero, particularly high-fat diet
increases obesity risk in the offspring [103]. A study has shown how maternal
uptake of folic acid altered the epigenome in an agouti mice model, causing a
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shift in the coat color of offspring [104] (Fig. 1.2). In another example, ma-
ternal diet with genistein, a phytoestrogen from soy, protected the offsprings
of agouti mice from inherited obesity through epigenetic alterations [105].
Figure 1.2: Maternal diet with different doses of methyl donors partially
restored DNA methylation related to agouti gene, causing a shift in off-
spring coat colors towards normal. Taken from Proc Natl Acad Sci USA.
2007;104(32):13056-61 [104].
Development
Epigenetic reprogramming takes place in the early stages of mammalian em-
bryo development. Still, a substantial number of epigenetic loci is not al-
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tered [106]. For example, hypomethylation of a transposable element up-
stream of the gene A in agouti mice is kept in offsprings, resulting in in-
heritance of ectopic expression of the Agouti protein [107]. Also, DNA
methylation is almost completely erased during two phases in mammalian
embryo development, namely gametogenesis (in oocyte or sperm) and early
embryogenesis [108]. Then, genes except housekeeping and tissue-specific
genes [109] are re-methylated. Specifically in females, X-chromosome inacti-
vation occurs in a random X chromosome through the mediation of X-inactive
specific transcript (Xist) non-coding gene. Promoter CGIs are reported to be
heavily methylated on the inactive X chromosome in somatic cells [110,111],
whereas the other non-CGI CpGs are mostly unmethylated on the inactive
X chromosome [112]. Heterochromatin is established on the inactivated X
chromosome, shutting down the expression of most of the genes [113].
Epigenetic modifications also play an important role in menstruation.
The epigenetic alterations in endometrium during the menstrual cycle are
mainly driven by the expression changes of epigenetic modulators [114], and
the expression of such genes are affected by ovarian hormones estrogen and
progesterone [115]. Histone acetylation regulates vascular endothelial growth
factor pathway (VEGF) [116] during angiogenesis and facilitates embryo im-
plantation [117](Fig. 1.3).
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Figure 1.3: Global acetylation levels of endometrial progenitor cells deter-
mined by western blotting during menstrual cycle, data taken from [117]
.
Global loss of DNA methylation in non-CpG islands is observed with
increasing age [6], while CpG islands tend to become hypermethylated. Hy-
permethylation is known to affect genes involved in slow wound healing [118]
and loss of teeth and hair [119]. Methylome changes are also associated
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with aging-related diseases, such as Parkinson’s disease [120], Alzheimer’s
disease [121], Huntington’s disease [122].
Diseases
Aberrant epigenetic modifications contribute to several effects in carcinogen-
esis, such as chromosomal instability, reactivation of transposable elements,
and loss of imprinting. It is estimated that promoter hypermethylation plays
a more dominate role than sequence mutations in gene silencing [123]. Global
hypomethylation is frequently observed during cancer progression, which may
cause overexpression of oncogenes [124,125]. In particular, hypomethylation
at enhancers are much more frequent than at promoters in colorectal can-
cer [124].
Hypomethylation of transposable elements, such as small interspersed
nuclear elements (SINE), and long interspersed nuclear elements (LINE)
is frequent in cancer. Given that LINE-1 comprises ∼ 17% of the hu-
man genome [126], LINE-1 hypomethylation has been reported in a variety
of cancers (bladder cancer [127], colorectal cancer [128, 129], gastric can-
cer [130], breast cancer [131], multiple myeloma [132], hepatocellular carci-
noma [133], urothelial carcinoma [134]), and leads to the activation of onco-
genes [127,128].
Moreover, dysregulation of transposable elements is responsible for chro-
mosome instability [135, 136], and contributes to chromosomal transloca-
tions in acute myeloid leukemia (AML) [137], T-cell acute lymphoblastic
leukemia (T-ALL) [138], chronic myelogenous leukemia (CML) [139], breast
cancer [140,141], gastric cancer [142] and ovarian cancer [143].
Imprinting disorders are found in ∼ 30% of colorectal cancer (CRC) pa-
tients [144]. In some cases, the insulin-like growth factor II gene (IGF2) is hy-
pomethylated, causing dual expression in both alleles. Although IGF2 over-
expression alone is not sufficient for tumorigenesis, it stimulates the growth
of many carcinomas [145], and leads to poor prognosis.
Centromeres are mostly hypermethylated in normal cells, but in cancer
they are found to be often demethylated [3], promoting mitotic recombina-
tion, and eventually possibly leading to aneuploidy [146,147].
1.1.4 Who are involved in epigenome regulation?
DNA methyltransferases
DNA methyltransferases (DNMTs) are involved in two roles: maintenance of
methylation (DNMT1) and de novo methylation of CpG sites (DNMT3a and
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DNMT3b) [148, 149]. DNMT overexpression is frequent in a variety of can-
cers, such as AML [150, 151], CML [150], breast cancer [152, 153], colorectal
cancer [154,155], hepatocellular carcinomas [156,157], pancreas cancer [158],
prostate cancer [159], and esophageal squamous cell carcinoma [160], and
causes global changes in the methylome. DNMT inhibitors prevent aberrant
methylation, can reverse hypomethylation of oncogenes and hypermethyla-
tion of tumor suppressor genes [157, 161], making tumors more sensitive to
chemotherapeutic treatment [162]. Cancer can evade immunoresponse by si-
lencing the expression of cancer-testis antigens, such as NY-ESO-1. Treating
with DNMT inhibitors can induce the expression of these antigens, allowing
them to be recognized by T cells [163].
Histone acetyltransferases
Histone modifications are performed by two types of modifying enzymes
known as epigenetic ”writers”, such as kinases, ubiquitin ligases, histone
methyltransferase (HMT) and histone acetyltransferase (HAT) and ”erasers”,
such as phosphatases, deubiquitinases, histone deacetylase (HDAC) and hi-
stone demethylases (KDM) which remove these modifications. Alteration of
histone-modifying genes are frequently observed in cancers [164]. For exam-
ples, HDACs regulate various cancer hallmarks, including cell differentiation,
cell cycle and proliferation, migration and metastasis, angiogenesis and apo-
tosis [165]. HDAC overexpression is frequent in a variety of cancers [166,167].
Hence, HDACs are considered as potential drug targets for cancer treatment
and HDAC inhibitors are currently under clinical trial for a variety of cancers,
such as glioblastoma [168–170].
In particular, enhancer of zeste homolog 2 (EZH2) is a histone methyl-
transferase which adds methyl group to lysine 27 on histone 3. EZH2 over-
expression is frequent in breast cancers [171], wherein it adds H3K27me3
to tumor suppressor genes, causes transcriptionally repression. Therefore,
EZH2 is a therapeutic target and EZH2 inhibitors are currently under devel-
oping for clinical trials [172].
Transcription factors
Transcription factors (TF) recognize specific DNA sequences [173], alone or
with other proteins in a complex. They can promote or block the recruit-
ment of RNA polymerase to specific genes [174,175]. The DNA methylation
level of the binding sequence can affect TF binding, and lead to increase
or decrease in transcriptional activity. For example, Yin et al. found that
34% are enhanced by CpG methylation of their recognition sequences, while
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the others might be inhibited or not affected [176]. The enhanced ones are
mostly belong to transcription factors of the extended homeodomain family.
Histone modifications and chromatin accessibility impact the binding ac-
tivity as well. Transcription factor binding requires the relaxation of chro-
matin, as it rarely binds to dense [177] or repressed [178] chromatin. Excep-
tions to this are so called pioneer factors such as FoxA1, which are capable of
binding condensed chromatin, leading to its rearrangement and recruitment
of further TFs.
In embryonic stem cells (ESC), gene expression that establishes and main-
tains ESC state is controlled by a few master transcription factors [179–181].
Whyte et al. found that the master transcription factors bind large clusters
of enhancers, termed as ”super-enhancers” [182]. The ESC master tran-
scription factors Oct4, Sox2 and Nanog were found to regulate each other
through binding to super-enhancers and form the a so-called ”core regulatory
circuitry” [183,184]. As such, super-enhancers are densely occupied by these
the master regulators during ESC development [182].
1.2 Bioinformatic approaches to the epige-
netic study
1.2.1 ChIP-Seq analysis
Chromatin immunoprecipitation sequencing (ChIP-Seq) is widely used in
resolving the genomic positions of histone modifications, transcription fac-
tors (TFs) and other non-histone proteins. In ChIP protocols, chromatin is
sheared to ∼ 150− 500 bp fragments, and a specific antibody is used to bind
the protein of interests. After purification, the bound DNA is sequenced
for analyzing the binding locations. Control samples (referred as ”input”)
which are not subject to immunoprecipitation, are often used in estimating
the background noises and correcting the biases from GC content [185, 186]
and copy number variation [187], etc. As sequencing costs decrease and more
histone antibodies are available, many different histone marks are profiled in
a variety of cell types or tissues [188].
Depending on the type of histone modifications (or ”histone marks”),
the binding regions either display sharp peaks or broad domains, whereas
TFs typically display sharp peaks [189]. The sharp peaks can be identified
without a sequenced control [190], whereas the identification of broad domain
typically requires control especially in case of low enrichment levels.
Enriched regions can be identified using bioinformatic tools called peak
callers. Peak caller usually determines the significance of the signal levels in
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enriched regions, and also estimates the false discovery rate (FDR) relative
to the control signal. MACS [191] and SICER [192] are two widely used
peak callers. MACS focuses on the local enrichment, and has initially been
developed to detect sharp peaks, while SICER joins spatial clusters of signals
into broad domain by setting gap size and window size, making it ideal for
calling broad peaks like H3K27me3 and H3K9me3. In its first version, MACS
used to truncate broad peaks into many separate small peaks. In the next
version MACS2, broad peak calling was added, which merges nearby highly
enriched regions into a broad region using a looser cutoff.
While peak callers allow one to discriminate the binding events or the
regions enriched for specific histone marks from background noise, in many
cases, one also needs to compare ChIP-Seq intensities in order to detect
differential binding. Many tools have been developed to perform compar-
ative ChIP-Seq analysis between two conditions, such as ChIPComp [193],
ChIPDiff [194], ChIPnorm [195], csaw [189], DBChIP [196], DiffBind [197],
MAnorm [198], RSEG [199], each specialized in particular scenarios (a deci-
sion tree model for tools selection was proposed by Steinhauser et al. [200]) in
terms of the availability of replicates or ChIP-Seq inputs. As an application
example, using DiffBind in quantitative investigation of estrogen receptor-α
(ERα) binding intensities in primary and metastasis breast cancer patients,
Ross-Innes et al. found that differential ER-bindings were associated with
the prognosis of breast cancer [201].
1.2.2 WGB-Seq analysis
Whole-genome bisulfite sequencing (WGB-Seq or WGBS) is widely used in
analyzing DNA methylation. In WGB-Seq, the DNA is treated with sodium
bisulfite. Following this treatment, unmethylated cytosines are deaminated
to uracils and converted to thymidines during sequencing, while methylated
cytosines are still read as cytosines. Using the sequencing coverage of methy-
lated and unmethylated reads, methylation levels are measured either as
beta-values (1.1) or M-values (1.2), where a constant offset α is added to the
denominator in cases where the sequencing coverage (Covmeth and Covunmeth)
is low. The beta-value ranges from 0 to 1 (unmethylated to fully methylated),
and is more intuitive, whereas the M-value usually has a much broader range,
but is more statistically valid in various tests [202].
Beta =
Covmeth
Covmeth + Covunmeth + α
(1.1)
M = log2(
Covmeth + α
Covunmeth + α
) (1.2)
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The beta-values and M-values are easily inter-convertible with formula
(1.3) and (1.4). M-values are widely used in many tools which detect differen-
tially methylated regions (DMR), such as MethylAction [203], RnBeads [204],
while other tools may directly infer DMRs using sequencing coverage [205]. I
explicitly use M-values in determining the methylation thresholds in section
(2.3.2).
Beta =
2M
2M + 1
(1.3)
M = log2(
Beta
1−Beta) (1.4)
1.2.3 Chromatin accessibility
Regions of open chromatin are associated with nucleosome-free regions ex-
hibiting enrichment of DNase I hypersensitive sites (DHS) [206,207]. DNase-
Seq [208], assay for transposase accessible chromatin using sequencing (ATAC-
Seq) [209] and formaldehyde-assisted isolation of regulatory elements and se-
quencing (FAIRE-Seq) [210] are often used as low-cost alternatives to factor-
specific ChIP-Seq for general purpose chromatin accessibility studies [211].
FAIRE-Seq does not need antibodies as it is based on formaldehyde
crosslinking. As nucleosomes depleted chromatin are very inefficiently crosslinked
to protein [212], their locations are captured by FAIRE-Seq for sequenc-
ing. In DNase-Seq, sequences bound by regulatory proteins are protected
from DNase I digestion, and are further sequenced for the identification
of open chromatin regions and hence potential binding regions across the
genome. DNase-Seq has high sensitivity at promoters [213], yet it has been
limited to the requirement for the presence of DHSs [214]. In ATAC-Seq,
Tn5 transposase carrying sequencing primers is used to cleave genomic DNA
at nucleosome-free regions. Deep sequencing of the purified regions provides
open chromatin locations in the genome.
Chromatin accessibility is closely related to enhancer activity, and has
been used in enhancer inference in a number of studies [215–217]. Especially
ATAC-Seq is increasingly used to map open and potentially active enhancer
regions in a cost effective way. Given that ATAC-Seq can be performed on
a very low number of cells (even down to 500 cells), it has the potential to
detect enhancers active only in rare subpopulations of cells and the resolution
to precisely identify the active enhancer region.
13
1.2.4 Chromatin states
Chromatin state represents a descriptive classification of genomic regions
that is based on specific combinations of chromatin-associated proteins and
histone modifications. A state describes the probability (between 0 and 1) of
the presence of a particular histone mark. For example, a promoter state may
have an emission probability of H3K4me3 close to 1 and H3K36me3 close to
0. Given m histone marks, the theoretical number of possible combinations
of these marks will be m! (factorial m). The number quickly becomes too
large to analyze when m > 4, yet some of the patterns are very infrequent or
produced from technical artifacts. There are several methods to generalize
these patterns. One of which is based on hidden Markov models (HMM) and
can be defined as (1.5).
λ = (A,B, pi) (1.5)
where A is a matrix of state transition probabilities, B is a vector of state
emission probabilities and pi is a vector of initial state distributions. A and pi
are initialized from Bernoulli or gaussian random variables, and refined using
the Baum-Welch algorithm. Transition probabilities represent the frequen-
cies of co-occurrence of each possible combination of the neighboring states.
The model is used to infer the chromatin segmentation from a sequence of
hidden states, using the Viterbi or the posterior decoding algorithm.
There are several tools implementing HMMs in chromatin states recog-
nition, such as ChromHMM [218], and EpicSeg [219]. ChromHMM allows
one to define chromatin states through the presence of histone marks, and
was widely used to annotate the epigenome in the ENCODE and Roadmap
projects. The epigenetic signals are assigned to non-overlapping bins of 200
bp (which roughly mimic the nucleosome DNA sizes). ChromHMM has been
applied on 111 Roadmap primary cell lines and 16 ENCODE cell lines with
six histone marks [220].
The interpretation of chromatin states is done according to prior biologi-
cal knowledge. For example, the combination of H3K4me1 with H3K27ac is
known to mark active enhancers, hence the corresponding state will carry this
name. As the exact number of chromatin states is unknown, a ChromHMM
model with a large number of states can be pruned so that the state which
has the least distance to the nearest is removed. Besides histone marks,
ChromHMM was also used in combination with ATAC-Seq and WGB-Seq
[221]. ChromHMM has been used in characterizing cancer subtypes [222,223],
and associated with other cancer-specific regions, such as hypomethylated re-
gions (HMR) [224], and differential gene expression [223].
14
1.2.5 High-throughput sequencing based techniques to
study 3D chromatin organization
Since chromatin conformation capture (3C) was invented by Dekker et al.
[225], various chromatin conformation capture techniques have been devel-
oped, including circular chromosome conformation capture (4C [226], or
”one-vs-all”), chromosome conformation capture carbon copy (5C [227] or
”many-vs-many”), chromatin interaction analysis with paired-end tag se-
quencing (ChIA-PET) [228] and Hi-C [229] (”all-vs-all”), which all allow
detection of long-range DNA interactions. In these methods, DNA-protein
complexes are crosslinked with formaldehyde. After ligation of the interact-
ing chromatin, the DNA is digested with restriction enzymes. The resulting
DNA fragments are then sequenced and mapped to the genome, allowing
identification of the genomic locations of the distal interacting chromatins.
The Hi-C resolution has been increased from initially 100 kb [230] to 40
kb [231] and, more recently, further down to 1kb [232]. Due to multiple steps
in the protocol and the low-yield of ligation products [233], Hi-C requires
large amounts of starting material, which makes it not applicable to small
amount of cells, for example from cancer biopsies.
In additional to Hi-C, ChIA-PET includes an immunoprecipitation step
to enrich for chromatin that is bound by a specific protein, e.g. transcription
factors, insulator proteins (CTCF) or the elements of the basal transcription
machinery (RNA-PolII, etc.). Capture-C [234] includes an additional pull-
down of the biotinylated fragments with magnetic beads, allowing to capture
fragments which interact with e.g. promoter regions.
Overall, the ”C” techniques can be used to generate contact probabil-
ity profiles and validate chromatin interactions, which make it essential in
predicting promoter-enhancer interactions.
1.2.6 Predicting promoter-enhancer interactions
Predicting chromatin interactions, especially promoter-enhancer (P-E) inter-
actions is an alternative approach when Hi-C datasets are not available or
impossible to obtain due to limited amount of samples. The most basic pre-
diction method is to simply select the nearest promoter of the enhancer, but
the accuracy is merely about 40% [235,236]. The accurany can be improved
by restricting the predicted interactions within the TAD domains [231,237],
or requiring conserved sequence patterns at the binding sites [238,239].
Other approaches select several candidate promoters within a certain dis-
tance from the enhancer, and predict the interaction probability based on
activities from other assays, such as DNase I hypersensitivity [240, 241].
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Recently, several supervised methods were developed to identify cell-type
specific P-E interactions. IM-PET [236], RIPPLE [242], and JEME [243]
were implemented based on a random forest (RF) classifer. They use epige-
netic modifications (DNase, H3K27ac, H3K27me3 and H3K4me1), promoter-
enhancer distances, binding motifs and enhancer RNAs (eRNAs) as features
and trained with known interactions from ChIA-PET data. The authors
claimed that they achieved high prediction accuracy (70%-90% of the AUPR)
on various cell lines [242,243].
1.3 Goals and structure of this thesis
In this thesis, I will describe two approaches in using epigenetic datasets in a
integrative manner in order to achieve a better understanding of regulatory
mechanisms.
In the first part (Chapter 2), I will a describe several bioinformatic ap-
proaches to analyze the epigenomic profile in a specific cancer type, namely
glioblastoma multiforme (GBM). In particular, I will describe possible ar-
tifacts in the identification of genomic regions enriched for specific histone
marks, and benchmark two peak calling algorithms. In addition, I will de-
scribe the chromatin states obtained in the different subtypes of GBM, and
discuss the differences observed. Following the observation of the subtype dif-
ferences, I will show how subtype classification can be obtained from histone
marks, and compare these classifications with alternate ones.
In the second part (Chapter 3), I will present a novel method which (i)
integrates multiple epigenetic marks into one single score, and (ii) takes into
account the contribution from various regulatory elements, namely promoters
and distal enhancers. This method uses a graph theoretical framework, and
can be applied to any differential analysis of the epigenetic profiles between
two conditions. Using random walk methods on the graph of enhancer-
promoter interactions, single genes can be ranked according to the amount
of epigenetic alterations in their regulome. I will show a comprehensive
benchmarking of this method using datasets from various cancer types and
developmental processes. This method can also take into account relations
between genes (such as gene-gene interactions) in the form of an embedding
network, from which gene modules can be extracted, and compared to specific
pathways.
In the last Chapter (Chapter 4), I will discuss the results and provide
some outlook.
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Chapter 2
Glioblastoma epigenetics
2.1 Introduction
Glioblastoma multiforme (GBM) is a deadly and frequent brain tumor in
adults [244]. In the WHO classification, it is classified as grade IV, and
the tumor cells are undifferentiated or anaplastic. Grade II and III gliomas
are termed lower-grade gliomas (LGG), and can in certain cases evolve to
secondary GBMs. The median survival time of patients who were diagnosed
as GBM in the United States is less than one year [245]. The cell of origin of
GBMs is still controversial, and various studies have studied to what extend
central nervous system (CNS) cells can leading to tumor initiation, with
mixed results. However, it is believed that neural stem cells (NSC) play a
central role in the GBM initiation.
Comparing to the normal brain cells, the tumor cells harbor a signif-
icant number of mutations, both in DNA sequences as well as epigenetic
modifications [246, 247]. Using gene expression datasets, GBMs were clas-
sified into four basic groups according to gene expression patterns, which
are proneural, neural, classical and mesenchymal [246], and characterized by
either frequent mutations or high expression of signature genes (Table 2.1).
The survival time for each subgroups after aggressive treatment is highest
in neural, followed by classical, mesenchymal, and proneural which has the
lowest survival time [246]. The gene expression classification was found to
be problematic afterwards because the proneural group contains two very
distinct subgroups (termed ”IDH” and ”RTK I”) which can be distinguished
by investigating their DNA methylation pattern.
GBMs with IDH mutations gain the ability to produce 2-hydroxyglutarate
(2-HG), which affects the function of enzymes that are dependent on α-
ketoglutarate [248], including DNA methyltransferase [249] and histone lysine
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demethylases [250, 251]. In the latest GBM classifier, the neural subtype is
no long present due to high normal brain cells contamination [252]. By
subtyping with DNA methylation from 450K methylation array, Noushmehr
et al. discovered that the IDH1 mutation status defines two distinct DNA
methylation patterns in 272 glioblastoma tumors from TCGA, and defined
two major subgroups called Glioma CpG island methylator phenotype (G-
CIMP) positive (CIMP+) and negative (CIMP-) [253]. Turcan et al. further
confirmed that mutated IDH1 has the capability to remodel the methylome
[254]. Besides IDH1, Sturm et al. also proposed another two subgroups
within the CIMP- defined by the mutation status of H3F3A gene [247].
Table 2.1: Glioblastoma classification and signature genes *
Mutation Overexpression
Classical EGFR EGFR
Proneural TP53, IDH1, PDGFRA PDGFRA
Mesenchymal NF1, PTEN, TP53
Neural neuronal genes
* Signature genes refer to the mutated and differential expressed genes from
Verhaak et al.
In this study, I analyzed six histone modification datasets of GBMs from
the DKFZ-HIPO project (Table 2.2). The 60 GBMs in this study were
classified into IDH (proneural), MES (mesenchymal), RTK I (classical) and
RTK II (proneural) using a previously published 450K methylation array
classifier [247], and the classification is in coincidence with WGBS and RNA-
Seq subtyping. Six histone modifications (H3K4me1, H3K4me3, H3K27ac,
H3K36me3, H3K9me3, H3K27me3) were analyzed using ChIP-Seq.
2.2 Regulatory regions in GBMs
2.2.1 Identification of enriched regions of epigenetic
marks
ChIP-Seq reads were mapped to the reference genome GRCh37/hg19 using
the Bowtie aligner. Uniquely mapped reads and individual input controls
were used for the peak calling with MACS2 [191] using default settings.
Broad peaks are generated both using SICER [255] and MACS2 with ”-
broad” option. The broad peaks were 1.5-3.2 fold longer than the narrow
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Table 2.2: GBM datasets in this study
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peaks, and 23%-42% less in number (except H3K9me3). Visual inspection
in IGV [256] showed that MACS2 did not detect many enriched domains for
broad histone marks (H3K9me3, H3K27me3), and ended up in underesti-
mating both in number and length of the peaks (Fig. 2.1).
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Figure 2.1: Comparison of length and number of peaks across histone marks
for two peak callers. SICER outperformed MACS2 in calling broad peaks.
The histone modifications show distinct patterns related to the subtypes.
To identify subtype specific enhancers and their associated pathways, I ana-
lyzed the peak calls of four histone marks (H3K4me1, H3K4me3, H3K27ac,
H3K27me3) in each subtype. The co-enrichment of distinct histone marks at
promoters and enhancers are classified into five functional categories, and fur-
ther filtered according to subtype specificity (Fig. 2.2). In order to identify
GBM specific alterations in promoter and enhancer regions, I also compared
with peak calls of normal brain samples from the Roadmap project [220]. In
total, there are 13 normal brain samples from six different brain tissues (An-
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gular gyrus, Anterior caudate, Cingulate gyrus, Hippocampus middle, Mid
frontal lobe, and Substantia nigra), and each has the same set of six histone
marks as this study.
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Figure 2.2: Schematic diagram of promoter and enhancer analysis.
2.2.2 Active and poised enhancers
I classified enhancers into two categories as active and poised ones. Active
enhancers are marked by both H3K4me1 and H3K27ac [235,257], and poised
enhancers do not have the H3K27ac mark [258]. Poised promoters are con-
sidered as the outcome of either pre-marking or persisting for extended time
after loss of activation [51]. I used the H3K4me1 broad peaks identified from
MACS2 to define enhancer regions. Similar to the methods in other stud-
ies [259, 260], subtype specific promoters and enhancers were identified by
requiring their existence in at least two samples from the same subgroup,
and only the regions with no H3K4me3 surrounding ±2 kb of the TSS were
considered as enhancers, otherwise they were considered as promoters. Ac-
tive enhancers and promoters are more frequent than the poised ones in both
numbers and genomic length in all four GBM subtypes (Fig. 2.3).
Signals of active enhancers were compared using an analysis of variance
(ANOVA) approach across the four subtypes, whereas H3K27ac enrichments
of the active enhancers were calculated with (2.1).
ScoreH3K27ac = log2(
CountH3K27ac
LibsizeH3K27ac
× Libsizemin + α
CountInput
LibsizeInput
× Libsizemin + α
) (2.1)
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Figure 2.3: Number and length of promoters and enhancers in each category.
where CountH3K27ac and CountInput are the total number of reads mapped
to the enhancer in H3K27ac and control datasets, respectively. LibsizeH3K27ac
and LibsizeInput represent the total library sizes for H3K27ac and control, re-
spectively. Libsizemin is calculated as min(LibsizeH3K27ac, LibsizeInput), and
a constant number α was added to stabilize enrichments when read counts
are low. Subtype active enhancers were selected with criteria (FDR <0.1,
and log fold change >1), which resulted in 343 IDH, 54 MES, 153 RTK I, 625
RTK II specific active enhancers. I performed functional enrichment analysis
of the neighbouring genes of subtype active enhancers using GREAT [261].
The enhancers are assigned to genes based on the ”basal plus extension” rule,
in which a regulatory domain of ±1Mb from the basal domain (5 kb upstream
and 1 kb downstream from the TSS) was searched. GREAT used the entire
genome as the background and identified a number of pathways (Fig 2.5) as
enriched with active enhancer regulation in each subtype. I selected a few
GBM relevant gene ontology (GO) terms as shown in Fig 2.5, wherein the
MES subtype has too few active enhancers and show no enrichment in any
of the databases.
From the GO enrichment of subtype specific active enhancers, the IDH
subtype has more enhancers neighboring with the genes of SREBP signal-
ing pathway, which is associated with poor survival in GBMs [262]. IDH
also has a significant amount of G-protein coupled glutamate receptor re-
lated enhancers, which have important roles in tumorigenesis [263]. On the
other hand, RTK II has several very significantly enriched enhancers asso-
ciated with well studied pathways in glioblastoma, such as ERBB signaling
pathway [264], and fibroblast growth factor receptor signaling pathway [265].
In addition, enhancers regulating neurotrophin signaling pathway are also
enriched in RTK II, which are connected with glioma invasion [266].
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Figure 2.4: H3K27ac signal in each subtype versus log fold changes of
H3K27ac by comparing each subtype to the other three subtypes. Subtype
specific active enhancers (FDR <0.1, and log fold change >1) are colored in
red.
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Figure 2.5: GO Biological Process of subtype specific active enhancers. Se-
lected ontologies from top ten enriched terms are presented, and only bars
with significant p-values are shown in each subtype.
2.2.3 Loss of promoter bivalency in GBMs
I also examined the genomic regions within ±2 kb of the TSS that are marked
with both H3K27me3 and H3K4me3 in normal brain, and defined as so-
called ”bivalent promoters”. I analyzed the promoters which lose bivalency
in GBMs. Among 2812 bivalent promoters from the normal brain tissues
(defined by the fact that at least 5 out of 8 samples have both H3K4me3
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and H3K27me3), 51%-57% become active in GBMs (at least three samples
in IDH, RTK I, RTK II, or at least two samples in MES lose H3K27me3),
while most of the remaining ones stay bivalent, and only a small proportion
become repressed by losing H3K4me3 mark (Fig. 2.6 a). GO enrichment of
activated promoters in GBMs show enrichment of glioma related terms (Fig
2.6 b), in which glutamate receptor activity in IDH and fibroblast growth
factor receptor binding in RTK I are also significantly enriched, suggesting
these two categories of genes undergo intensive epigenetic regulation with
both promoters and enhancers in GBMs. The MES subtype has a significant
number of genes related to neurotrophin binding which become activated,
and these genes are known to be involved in epithelial-mesenchymal tran-
sition (EMT) [266], which is a typical process in the MES subtype. The
common bivalent promoters in both normal brains and GBMs are enriched
in developmental genes such as the Hox genes, which are also often observed
in ESCs in previous studies [267,268].
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Figure 2.6: The status and functional enrichment of normal brain bivalent
promoters in GBMs. (a) Each cell in the figure represents a bivalent pro-
moter in normal brain, which can be either activated (loss of H3K27me3)
or repressed (loss of H3K4me3), or still bivalent in one of the GBM sub-
types. (b) GO Molecular Function enrichment of subtype activated bivalent
promoters. Terms are measured with combined scores from EnrichR in each
subtype.
An investigation on individual promoters reveals that a number of GBM
related genes have been activated by losing the H3K27me3 marks. For ex-
ample, RUNX1 is involved in migration, invasion, and angiogenesis of GBM
cells [269]. A general loss of H3K27me3 marks at RUNX1 promoters has been
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observed in all GBMs as opposed to the normal brain, and led to higher gene
expression. The same is true for MYC and MYCN, which are oncogenes
highly expressed in GBMs [270, 271]. A few genes are found with exclusive
loss of H3K27me3 in RTK I subtype, including ASCL1 [272,273], DLL3 [274],
NKX2.2 [275], OLIG2 [276,277], and SOX11 [278], and lead to specific gene
expression in RTK I (unpublished data from other studies). H3K27me3 sig-
nals in the house keeping genes are also compared, in which both GBMs and
normal brains have low levels of H3K27me3 (Fig. 2.7).
Figure 2.7: IGV screenshots of a few genes losing H3K27me3 marks in pro-
moters, led to higher gene expression in all GBMs or RTK I. Colors of the
H3K27me3 and H3K4me3 track represent IDH in red, MES in blue, RTK I
in green, and RTK II in purple.
2.2.4 Epigenetic subtyping in GBM
To get a general view of subtype specific histone modification patterns in
GBMs, I performed differential binding analysis with DiffBind [197]. GBM
subtyping using histone marks is not as common as subtyping using DNA
methylation or RNA expression. Not only because the costs of ChIP-Seq are
not attractive comparing to methylation array, but also because the normal-
ization of histone marks is more difficult than DNA methylation, since the
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intensities of histone modification at genome loci can range from 0 to an in-
definite value, whereas DNA methylation only ranges from 0 to 1. However,
histone mark subtyping for this project is of practical use, since it allows me
to validate the accuracy of peak calls by comparing to the known subtype
classifications. Here I show that for some of the histone marks subtyping is
feasible. With proper peak caller, one can also achieve very good accuracy
in GBM classification (Fig. S2).
A number of heatmaps (Fig. S2) using only one histone mark were gener-
ated using DiffBind, which presented an initial clustering of the samples from
the cross-correlations of merged peak set. Every peak caller and every histone
mark individually, is inadequate to produce a satisfying classification of the
GBM subtypes (Fig. 2.8). SICER has overall best accuracy for subtyping.
It is noticeable that the classification with H3K4me3 peaks from MACS2
and H3K27me3 peaks from SICER both achieved the best performance, tak-
ing as a reference of the classification based on DNA methylation patterns.
From visual inspection of a large number of loci in the genome browser, I
assume that the H3K4me3 peaks from MACS2 are accurate and H3K4me3
is indeed a good classifier which has been also shown in breast cancer sub-
typing [279]. From visual inspection again, H3K27me3 peaks from SICER
are more accurate than those from MACS2. As H3K27me3 modifications are
often found mutually exclusive with DNA methylation on a majority of ge-
nomic locations [280], classification using H3K27me3 is expected to achieve
similar accuracy as the DNA methylation classifier.
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Figure 2.8: Number of mis-classified samples across histone marks and peak
callers. The average number of mis-classified samples is 5.6 (indicated with
red dashed line), whereas SICER succeeded in lowering the number for every
epigenetic mark expect H3K36me3.
Making use of all histone marks seems a more feasible solution [281]. But
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instead of pooling all peak sets together, I built the concatenation of the
feature matrices of six histone marks computed by DiffBind, which produced
an augmentation of feature matrix (2.2).
Overall(k×(m+···+n)) =
[
H3K27ac(k×m) · · · H3K9me3(k×n)
]
(2.2)
where k indicates the number of samples, and m, · · · , n are the number
of merged peaks for each mark. Clustering with the overall matrix gives the
most similar classification with the subtype definitions (Fig. 2.9).
Figure 2.9: Correlation heatmap using all bound sites from all histone marks
2.3 Chromatin states
In this part, I performed analysis on the general combination of six histone
marks, which is referred to as chromatin states. The analysis focuses on a
small number of most prevalent combinations of histone marks, to interpret
the validity of the model and transitions between different subtypes.
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2.3.1 Roadmap 18-states model
Here I took the emission probabilities and transition probabilities from the
18-states model of the Roadmap project [220], and applied this model to
each GBM sample to infer the epigenome states. Two approaches are em-
ployed in transforming the count data into the binary values. Either from
a Poisson background distribution built in ChromHMM, which is estimated
from aligned reads with a sample-specific threshold, or from the presence or
absence of peaks from the peak callers. After examining the ChromHMM
segmentations from both approaches, I found that the latter one did not work
well on certain types of chromatin states. The reason is that the border of
either short or long peaks of some histone marks identified by MACS2 or
SICER are not exact, making the combination biased towards a few types
of chromatin states (Fig. 2.10). From these results, the ChromHMM model
from MACS2 narrow peaks (with looser cutoffs, otherwise the H3K9me3
and H3K27me3 peaks were largely absent) (Fig. 2.10 a), MACS2 broad
peaks (Fig. 2.10 b), and SICER peaks (Fig. 2.10 c) over-represented ZNF
repeats, weak polycomb repressed, and promoters/enhancers, respectively,
while ZNF repeats and weak polycomb repressed were largely missing in
the ChromHMM model from MACS2 broad peaks and SICER peaks, re-
spectively. Selective combinations of MACS2 broad peaks and SICER peaks
still over/under-estimated weak transcription (Fig. 2.10 d,e,f), polycomb
repressed (Fig. 2.10 d,e,f), and enhancer (Fig. 2.10 f) states.
In general, the built-in binarization command ”binarizeBam” is more
accurate in making binarized inputs, owing to that it is capable of setting
different cutoffs specific to the Poisson background distribution of different
marks, as opposed to using the same cutoff for all datasets. The final model
confirmed the findings from section (2.2.3) that many gene promoters indeed
lose bivalency (Fig. 2.6 and 2.11).
Since ChromHMM only uses the histone marks, I wanted to analyze the
relationship of chromatin states with DNA methylation. Therefore, I took
the beta-values of DNA methylation from corresponding samples, and plotted
subgroup-wide distributions of DNA methylation in each chromatin states.
From (Fig. 2.12), the active promoters show the lowest methylation lev-
els as expected, and the gene bodies, which correspond to the transcription
states, are highly methylated. Enhancers have an overall relatively high level
of DNA methylation, probably due to a number of enhancer located within
gene bodies (10%-20% across samples, primarily intronic). The RTK I sub-
type has the overall lowest DNA methylation, which can also be observed
from the genome-wide patterns of methylation. The polycomb repressed
chromatin (PRC) regions show a relatively low methylation as well, which
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Figure 2.10: Various combinations of MACS and SICER peak calls in chro-
matin binarization (bottom half circle), compared with the binarization from
the built-in function of ChromHMM (top half circle). The ChromHMM seg-
mentations are made with the 18-states model from the Roadmap project,
and the genomic length from all combinations and the built-in binarized in-
put are compared against each other. Chromatin states and their transitions
are colored the same as Fig. 2.12.
is also observed in prostate cancer [282], owing to the mutually exclusive
occupancy of PRC and DNA methylation at CpG sites. In addition, bivalent
promoters in the normal brain samples are very lowly methylated compar-
ing to the tumor samples. This phenomenon is also frequently observed in
other cancers, such as colorectal cancer [283,284], prostate cancer [282,285],
lymphomas [286] and cancer cell lines [287]. As a result, hypermethylation
in bivalent promoters makes the expression of these genes even lower.
State transitions between subtypes and normal brain samples show that
the promoter and transcription states are relative consistent across samples,
and switching usually takes place between different variants of the same cat-
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Figure 2.11: Bivalent regions as proportions in GBMs and normal brain.
GBMs have an overall trend of losing bivalent and repressed chromatin states.
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Figure 2.12: DNA methylation distributions of chromatin segmentation of
the 18-states model
egories, e.g. from weak transcription to strong transcription, or from active
promoter to bivalent promoter (Fig. S3). The other states are more variable,
and transitions are more frequent between different categories, e.g. from en-
hancers to heterochromatin. There is no noticeable excessive transition of
any state between subtypes, or between GBMs and normal brains, yet the
genomic regions of enhancers still show strong subtype specificity (Fig. 2.13).
2.3.2 Customized ChromHMM model
Apart from segmenting the GBM epigenomes into a fixed combinations of
chromatin states, I also learned several novel specific models from the char-
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Figure 2.13: Chromatin states comparison. (a) Genomic length of chro-
matin states, from the inner circle to outer circle are: normal brain, IDH,
MES, RTK I, RTK II. (b) States transition shown in percentage between five
IDHs and seven normal brain samples. Promoter and transcription states
are more consistent as transitions mainly occur between the active/poised or
strong/weak variants.
acteristics of epigenetic marks in each subtype. Learning a new model from
binarized GBM inputs gives a different number of states. In these models,
GBMs show a lack of bivalent domains, especially bivalent enhancers, which
is possibly a sign of dysregulation (Fig. 2.14). This also confirms the obser-
vation made previously of a general loss of bivalency in GBMs compared to
normal brain tissues.
Besides modeling with the pre-defined ChromHMM model from Roadmap
and the same histone marks (Fig. 2.14), I profiled my own model using six
histone modifications, and DNA methylation. In order to binarize the CpG
sites into two mutual exclusive categories, I took the M-values and fitted a
Poisson model. Plot of genome-wide CpG sites for each GBM subtype (Fig.
2.15) shows that the M-values follow a clear Poisson distribution, while the
beta-values display a bimodal distribution. Therefore, the M-value represen-
tation is more homoscedastic and statistically valid in methylation analysis.
M-values of every 200bp bins are calculated from the average methylation
level for each sample. By fitting the M-values to sample-wise Poisson models
and defining DNA methylation below the respective threshold as unmethy-
lated (Fig. 2.16), I got 34%-38% of the 200bp bins across samples as un-
30
TssA
TssW
EnhA
EnhP
EnhB
TssB
 
TssP
TssA
Tx
EnhG
EnhG
Tx
Tx
Het
Het
Quies
PRC
Tx
IDH
EnhA
TssB
TssA
Tx
TssP
TssA
TssA
Ac
EnhA
EnhA
EnhA
Tx
Tx
Tx
Het
Quies
PRC
PRC
EnhB
EnhP
EnhB
TssB
TssP
TssA
TssA
Tx
Tx
Tx
PRC
PRC
Het
Quies
Ac
EnhA
EnhA
EnhG
Tx
Tx
Tx
PRC
PRC
Het
Quies
EnhP
EnhB
EnhA
EnhA
Tx
TssA
TssA
TssP
TssB
EnhB
EnhB
MES RTK I RTK IINormal brain
Figure 2.14: Comparing the 18-states model learned from GBM binary in-
puts.
methylated.
(a) IDH beta (b) MES beta (c) RTK I beta (d) RTK II beta
(e) IDH M-value (f) MES M-value (g) RTK I M-value (h) RTK II M-value
Figure 2.15: Density plot of beta-values and M-values in each GBM subtype.
Since there is no obvious way of deciding how many chromatin states
I should use in training the model, I trained a series of HMMs with states
ranging from 15 to 30 for 200 iterations with the default initialization method,
and estimated the optimum number of states using Bayesian information
criterion (BIC), which is defined as (2.3).
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Figure 2.16: DNA methylation thresholds across samples. Red, blue, green,
purple represents IDH, MES, RTK I, and RTK II, respectively. Methylation
level above thresholds are considered as methylated.
BIC = ln(n)× (m2 + k ×m− 1)− 2ln(Lˆ) (2.3)
where k indicates the number of parameters of the underlying distribu-
tion of the observation process. As the Poisson distribution has only one
parameter, hence k = 1. m indicates the number of states, and n indicates
the total length of all the observation sequences that the HMM was trained
with, which is the number of bins used to train the model. Lˆ is the max-
imized value of the likelihood function of the model, which was computed
by ChromHMM. Generally, the BIC becomes lower as the number of states
increases.
I started from the model with 30 states, which has the lowest BIC score
among 16 models, and iteratively removed states from this model with the
”StatePruning” command in ChromHMM. The emission probabilities of the
removed states are redistributed to its transitioned states uniformly. After-
wards, initial parameters were estimated from the resulting set of models for
learning another model with reduced number of states. Using the initial pa-
rameters from the pruned model, I relearned a model with reduced number
of states until it did not contain duplicated states and infrequent states (
≤ 0.05% of genome coverage), and still contains the imperative states in-
cluding active promoters/enhancers, bivalent promoters, transcription, het-
erochromatin, and polycomb repressed regions. The final model contains 23
states, in which 53% of the genome is in a high methylation states. Promoters
in this model fall into two distinct groups, either active and lowly-methylated,
or poised and high-methylated. Enhancers can be either highly-methylated
or lowly-methylated, regardless of their active status (Fig. 2.17).
In summary, epigenetic profiling using my own models leads to more
refined states, especially when DNA methylation is included. Either the
technical bias in different histone marks causes heterogeneity in chromatin
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Figure 2.17: A ChromHMM integrating DNA methylation as chromatin
states
states modeling, or the GBMs really have a disorganized composition of
chromatin states. Either way makes the comparison of chromatin profile
across samples more complicated. Therefore, using the same chromatin state
model, which is the Roadmap 18-states model, seems to be a good solution
in comparative chromatin states analysis.
2.4 Subtype specific differential histone mod-
ification patterns
As I learned from the differential expression profiles of GBMs, differential hi-
stone modification sites (DHMSs) located in the vicinity of genes contribute
to a number of subtype specific gene expressions (Fig. 2.7). Most of the dif-
ferential binding site detecting tools perform comparison between only two
biological conditions [189,201,288], and they are not suitable in discriminat-
ing subtype specific differential binding for multiple conditions. While one
can treat multiple conditions as one condition and compare with the rest, this
approach is questionable when there is high heterogeneity in the conditions
which are grouped to form the control.
In the GBM study, I assume the presence of 16 differential binding pat-
terns, which are (1) four cases for which bindings are only present in one
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subtype (Fig. 2.18b 2-5), (2) six cases for which bindings are present in ei-
ther two subtypes (Fig. 2.18b 6-11), (3) four cases for which bindings are
present in either three subtypes (Fig. 2.18b 12-15), (4) two cases for which
are not differential binding, either bound on all subtypes, or bound on none
of the subtypes (Fig. 2.18b 1,16). ANOVA does not allow one to discover
differential patterns specific to more than one subtype. However, such pat-
terns are believed to be present as for example IDH and RTK I belong to
a common subgroup (at least from the point of view of gene expression),
namely the proneural group.
Hence I developed a new method in calling subtype specific differential
binding events, which uses deep neural network to classify epigenome signal
into all theoretical binding patterns. The method is efficient in identifying
differential binding patterns specific to more than one subtype, and will be
useful in more complex binding patterns recognition, e.g. specific binding
involving normal brain tissues and low grade glioma in this study.
2.4.1 Simulated data
In order to train the neural networks, I built simulated datasets. Synthetic
data has been widely used in both physics [289] and biology, e.g., differential
binding [189] and expression patterns recognition [290]. Due to the lack of
observations of some patterns in real data, synthetic data can be used for
training the differential binding model. In this scenario, the ”bound” and
”unbound” level of H3K27ac signals can be represented from two skewed
distributions, with each ranges from 0 (lowest binding signal) to 1 (highest
binding signal), and 10,000 cases are sampled from each of the distributions
(Fig. 2.18 a).
Since every subtype only has two binding states, I generated 24 sets of
synthetic data as much as the number of patterns I wish to discover. The
datasets are labeled as ”1, 2, 3, · · · , 14, 15, 16” for training with a supervised
learning approach (Fig. 2.18 b).
2.4.2 Differential modification patterns from neural net-
work classifer
Neural network (NN) is an algorithm which can simulate any mathematical
function. Here I use a feedforward neural network to classify the H3K27ac
binding into 16 categories. The input to the NN is a 20-dimensional vec-
tor (one dimension for each sample) representing each case in the synthetic
data. I used a three-layer model (Fig. 2.19). In the fully-connected (dense)
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(a) Densities of two sample distributions.
D1 and D2 are two beta distributions from
different parameters, with D1 representing
enrichment in epigenetic signals, and D2
representing depletion in epigenetic signals.
13 14 15 16
9 10 11 12
5 6 7 8
1 2 3 4
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
s
ta
n
d
a
rd
iz
e
d
 s
ig
n
a
l
(b) Distributions and labels of synthetic
data for all combinations from the four
subtypes. Every sample in each subtype
is sampled from the same distribution,
wherein red, blue, green, purple represent
IDH, MES, RTK I, and RTK II, respec-
tively.
Figure 2.18: Synthetic data distributions.
layer, each layer’s input can be represented using (2.4) from the inputs of it’s
previous layer.
aij = σ(
∑
k
(wijk · ai−1k ) + bij) (2.4)
where σ is the activation function, and in the ith layer, wijk denotes the
weight from the kth neuron in the previous layer to the jth neuron, bij rep-
resents the bias of the jth neuron, and aij is the activation value of the j
th
neuron.
In the dense layer, the network applies a rectified linear activation func-
tion (ReLU) (2.5). I also added a dropout layer between every two dense
layers to prevent overfitting. The final layer consists of 16 neurons, which
equals the number of patterns I want to predict.
σ(x) = { 0 if i < 0
x if i ≥ 0 (2.5)
To train the model, I chose a function called cross-entropy cost function
to adjust weights and biases after every iteration (2.6).
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Figure 2.19: Model architecture of deep neural network
CCE(W,B, S
r, Er) = −
∑
j
[Erj ln a
L
j + (1− Erj ) ln (1− aLj )] (2.6)
where W is the neural network’s weights, B is the neural network’s biases,
Sr is the input of a single training sample, and Er is the desired output of that
training sample. To minimize the loss of cost function, I chose one stochastic
gradient descent function frequently used called ”RMSProp” (Root Mean
Square Propagation) (2.7).
θt+1 = θt − η√
E[g2]t + 
gt (2.7)
where η is the learning rate, E[g2] is the RMSprop running average of the
past squared gradients,  is a fudge factor for preventing divide-by-zero, and
gt is the gradient.
After 100 epoch of training, the network reached 95% accuracy on the gen-
erated labels. Comparing the network approach to classical k-means [291],
it partitions the data into much more unbalanced groups (Fig. 2.20). Look-
ing at the clusters produced from k-means with 16 centers, all the cluster
centers are well spread, and the size of groups are balanced (Fig. 2.21 a,c).
However, the patterns from k-means does not really reflect the differences
in subtype specificity, as the clusters mainly differ in overall binding levels
but not necessarily in binding shapes (Fig. 2.21 a,c). On the other hand,
although some patterns in the NN do not have the same level of signals (typ-
ically the all ”on” and all ”off” binding patterns, Fig 2.21 b,d), the patterns
are much more subtype specific. Most importantly, some patterns discovered
by NN are not present in the k-means clusters, and these patterns are still of
biological importance as will be discussed later.
In the subtype specific active promoters, I identified several genes which
are in concordance with biological processes of GBM subtypes (Fig. 2.22).
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Figure 2.20: Differential binding sites projected to discriminant coordinates.
Each predicted category is filled with a distinct color. The sixteen patterns
are not linearly separatable in these views.
For example, mesenchymal specific active gene CXCL14 [292] and SGMS2
[293] have been reported to play an important role in epithelial-to-mesenchymal
transition (EMT), which is associated the tumor differentiation in the MES
subtype [294]. BCAT1, which is only expressed in IDH wild-type tumors,
is exclusively inactivated in IDH subtype, which is reported for aberrant
BCAT1 promoter methylation as well as promoter deacetylation [295]. KCND2,
a potassium voltage-gated channel gene [296] in glioblastoma patients corre-
lated with poor survival, is highly expressed in RTK I [297]. Inactivation of
OLIG2 in glioma stem cells (GSCs) results in mesenchymal phenotypes [297],
and OLIG2 is lowly expressed in MES in accordance of its lack of H3K27ac.
Furthermore, loss of OLIG2 function results in mesenchymal transforma-
tion in proneural GBM subtype [298]. The ASCL1 is associated with high
H3K27ac levels in all GBM subtypes except MES, and is also reported lowly
expressed in mesenchymal and normal brain [273].
In summary, the deep neural network classifier presented accurate pattern
recognition in the simulated data with conceived patterns, while these pat-
terns have been proven useful in associating genes with the subtype specific
pathways. As any pattern can be generalized in synthetic dataset for super-
vised learning, the deep learning approach might be proven useful in many
other applications in the GBM study, such as recognition of specific epige-
netic patterns in transcription factor binding sites, or co-occurrence patterns
of multiple epigenetic marks.
37
ID
H
M
E
S
R
T
K
 I
R
T
K
 I
I
ID
H
M
E
S
R
T
K
 I
R
T
K
 I
I
ID
H
M
E
S
R
T
K
 I
R
T
K
 I
I
ID
H
M
E
S
R
T
K
 I
R
T
K
 I
I
(a) Promoter patterns by k-means
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(c) Enhancer patterns by k-means
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(d) Enhancer patterns by NN
Figure 2.21: Differential binding patterns discovered from two approaches.
Although k-means produced more balanced clusters, the patterns of interest
were not all present (in red frames). On the contrary, the clusters in NN are
unbalanced, but have clearer subtype specific patterns.
38
9IDH
MES RTK I
RTK II
4937
(a)
72
IDH
MES RTK I
RTK II
5822
(b)
(c)
Figure 2.22: Differential H3K27ac modification specific to combinations of
subtypes. (a) Number of differential H3K27ac promoters specific to the com-
bination of subtypes. (b) Number of differential H3K27ac enhancers specific
to the combination of subtypes. (c) A few examples with differential H3K27ac
levels from IGV screenshots.
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Chapter 3
Integrative analysis of
differential epigenetic
alterations
3.1 Introduction
Integrating multi-omics data is challenging due to high variability and noises
across different data types, yet it is essential in cancer research since cancer
usually harbors all type of alterations, either in DNA sequences or epigenetic
modifications. Although tools such as ChromHMM have proven their useful-
ness in studying the combinatorial patterns of multiple epigenetic marks, it
is limited to binary measurement such as presence or absence of the peaks.
In case where enrichment peaks are present in all biological conditions, the
intensity of epigenetic modification level may dramatically affect the binding
probabilities. Therefore a quantitative comparison between epigenetic data
is necessary in understanding the impact of a binding event. However there
are very limited ways in doing this. Although meta-analysis [299] and time
course analysis [300] approaches are common in RNA-Seq studies, they a
generally not applicable in studying multiple epigenetic marks. In this chap-
ter, I present my approach in integrating multiple epigenetic datasets, which
leads to more insightful results in understanding the underlying biological
relationship of epigenetic alterations.
In this approach, I will deliberately treat gene expression independently
of epigenetic modifications. One of the justifications for this choice comes
from the concept of epigenetic priming, an event in which epigenetic mod-
ifications initiate before gene expression. Hence, epigenetic alterations and
gene expression appear to be decoupled from this point of view. The notion
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of epigenetic priming is important in cancer studies because it might allow
one to identify potential oncogenic processes through epigenetic alterations
before they become detectable from gene expression or at protein level. To
investigate the concept of epigenetic priming, I considered datasets contain-
ing different time points during developmental progression. For example, I
studied four stages in neural progenitor cells (NPC) development into neu-
roepithelial (NE, day 12), early radial glial (ERG, day 12), mid radial glial
(MRG, day 35) and late radial glial (LRG, day 80), in which Ziller et al.
observed that gain of H3K4me1 and loss of DNA methylation appeared in
the early stages of the differentiation from ESC to NPC [301]. By comparing
the epigenetic patterns in promoter regions of NE stage to gene expression
patterns of all five stages, the result shows that the correlations of epige-
netic marks with expression at later stages, as opposed to the NE stage,
reaches highest level (Fig. 3.1), indicating the expression level is more re-
lated to the epigenetic modifications in earlier stages. Comparing to histone
modifications, DNA methylation have longer term effect, which confer later
expression in development [302]. Epigenetic priming is the reason why my
approach focuses mostly on epigenetic alterations rather that gene expres-
sion. The delay in gene expression in this case is understandable since time is
needed for mRNA accumulation after the epigenetic regulations take place.
To address such concepts in differential epigenetic analyses, I developed
a new method termed ”cancer regulatory landscapes” (crl) which integrates
the quantitative information from multiple epigenetic marks, on genome-
wide non-coding regulatory elements, allowing one to discover significantly
epigenetically altered genomic regions and pathways. In the benchmarking, I
proved that the genes of interests found using this method are highly relevant
to the cancer and developmental test cases.
3.2 Data sources
3.2.1 Epigenetic datasets
As illustrated in Fig. 3.1, both histone modifications and DNA methylation
can exhibit epigenetic priming. Besides epigenetic modifications in promot-
ers, I also included genome-wide epigenetic alterations in non-coding reg-
ulatory elements, which covers both alternative promoters and enhancers.
With WGBS data I am able to evaluate the effects of lowly methylated
regions (LMRs) inside enhancers, which have been shown to contribute to
its activity [303]. Genome-wide epigenome cohorts are publicly available
from many consortia, such as NIH Roadmap Epigenomics [304], ENCODE
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Figure 3.1: Epigenetic priming in neural progenitor development stages.
Each histone mark has two replicates, and Spearman correlation between
epigenetic patterns of the NE stage and gene expression of all stages are
shown. Histone modifications present short-term effects, while DNA methy-
lation present long-term effects.
[188], Blueprint [305], and the International Human Epigenome Consortium
(IHEC) [306]. These resources allow me to investigate the epigenetic rela-
tionships between embryonic stem cells and differentiated cells, or between
tumor and normal tissues (Table 3.1).
Due to the public policies of some data providers, their data are generally
provided for visualization purpose. Mostly only Wig and BigWig format
files [307] are accessible, rather than raw sequences (Fastq) or alignment
files (BAM/BED). Therefore statistical methods specific to raw counts [308,
309] are not applicable in my study. The peak calls were done by these
data providers, and these peak regions are used in the validation of cell-type
specific enhancers in later sections.
For restricting the epigenetic comparisons to the genomic loci of interests
(promoters and enhancers), I downloaded genomic coordinates of promoters
from the eukaryotic promoter database (EPD) [310], and enhancers from the
GeneHancer database [311]. There are ∼ 285,000 enhancers in GeneHancer
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Table 3.1: Test cases for phenotypic studies.
Tests Controls Num.* Data** Accession
codes/src
Neural Progenitor
Cells (NPC)
Embryonic stem cells 8 61 GSE16256
Neuroepithelial (NE) Embryonic stem cells 5 10 GSE62193
Early radial glial
(ERG)
Embryonic stem cells 5 10 GSE62193
Mid radial glial (MRG) Embryonic stem cells 5 10 GSE62193
Mesenchymal stem
cells (MSC)
Embryonic stem cells 8 51 GSE16256
Trophoblast stem cells
(TSC)
Embryonic stem cells 8 64 GSE16256
Chronic lymphocytic
leukemia (CLL)
B cells from healthy
cases
4 121 CEEHRC
Lower grade glioma
(LGG)
Hippocampus middle,
Inferior temporal lobe,
Mid frontal lobe
7 112 CEEHRC,
GSE17312
Colorectal cancer
(CRC)
Sigmoid colon from
healthy cases
7 154 CEEHRC
Papillary thyroid can-
cer (PTC)
Thyroid from healthy
cases
7 54 CEEHRC
* Number of epigenetic marks.
** Number of epigenetic datasets.
database, incorporated from four different sources: the Encyclopedia of DNA
Elements (ENCODE) [312], the Ensembl regulatory build [313], the VISTA
Enhancer Browser [314], and the functional annotation of the mammalian
genome (FANTOM) project [235]. This database contains enhancers for a
large number of cell-types and cell-lines, and tissues. Both datasets were
converted from GRCh38 to GRCh37 using the LiftOver tool [315].
The promoter coordinates were extended to ±1000 base pairs around
the original coordinates. A BigWig file consists of a number of blocks, each
containing a declaration of a fixed or variable genomic region. The numerical
signals from BigWigs for region i ∈ [m,n] were calculated as Si =
∑n
m si,
where the promoter/enhancer ranges from m to n, and si is the signal for each
genomic window in the region. The enhancers from GeneHancer database are
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collected from all tissues. To avoid unspecific enhancers, I require enhancers
to overlap with H3K4me1 peaks of at least two samples in the tissue I am
studying. Fig. 3.2 shows the number of common and specific enhancers
among four cancer types.
6
3071
CLL
CRC LGG
PTC
Figure 3.2: Number of common and specific cancer enhancers among four
cancer test cases.
3.2.2 Data processing procedure
The epigenetic data between samples have large heterogeneity and must be
normalized before statistical comparisons can be made. The promoters and
enhancers are of different genomic length, so I divided the intensities by
their length before the normalization. The data are heavily right skewed,
and I used Box-Cox transformation (3.1) to transform the data into normal
distributions.
y(λ) =
{
yλ−1
λ
, if λ 6= 0
log y, if λ = 0
(3.1)
By finding the most likely λ that minimizes the variation, a universal λ
of ∼ 0.182 was proposed to apply to all data. After power-transformation,
I checked the global variability across and within biological groups using
quantro [316]. It estimated the variabilities were caused by technical variation
(e.g. batch effects), and a global normalization is applicable.
I used quantile normalization which was firstly implemented in microarray
analysis by Bolstad et al. [317], and quickly adopted to a variety of data types
such as RNA-Seq analysis [255, 318–320], DNA methylation [321], ChIP-
Seq [322, 323]. This method makes the quantiles of each distribution equal.
After normalization, except a number of genomic regions showing no signal
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of epigenetic modifications, the rest of the data follows normal distribution
(Fig. 3.3), which is the prerequisite for using differential principal component
analysis in the next step.
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Figure 3.3: Data distributions of epigenetic marks after Box-Cox transfor-
mation.
Correlation structures of data
I firstly compared the aforementioned processed data with gene expression to
verify that the normalization maintains the correlation structure. The result
shows that for each sample, the gene expression positively correlates with
the epigenetic signal in the promoter regions of H3K4me3 and H3K27ac, and
negatively correlates with the epigenetic signal of H3K9me3 and H3K27me3
(Fig. 3.4. a).
Although some epigenetic marks correlate very well with the gene expres-
sion of the corresponding dataset, I wanted to perform a differential analysis
between conditions. Therefore, I tried to resolve the relationships of expres-
sion differences and the differences of epigenetic modifications between two
biological conditions, e.g. tumor cells and normal cells. Again, I normalized
the data using quantile normalization, making the two groups have same
standard deviations. Afterwards I took the average differences of epigenetic
modification levels and gene expression levels. The correlations of differential
histone modification with expression in the promoter regions are consider-
ably lower comparing to the previous test, but still correlate positively with
activation marks and negatively with repression marks (Fig. 3.4. b). The
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weaker correlations may be attributed to the fact that I have not included
the epigenetic modification outside of the promoter.
(a) Correlation of histone mark with RNA expres-
sion
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(b) Correlation of histone mark differ-
ences between two groups with gene
expression differences
Figure 3.4: Correlation of epigenetic marks with gene expression
Modifications at oncogenes and tumor suppressor genes
With respect to the role in cancer development, it has been known that
hyperacetylation of oncogenes (OG) results in an increase of their gene ex-
pression, whereas hypoacetylation of tumor suppressor genes (TSG) reduce
their expression levels [324]. OG and TSG are both retrieved from a compiled
list by Walker et al. [325] (Supplementary table S1). Here I used 11 house-
keeping genes (HKG) with constant expression level from RNA-Seq profiles
as control [326]. The epigenetic modification levels around the TSS of HKG,
OG and TSG are not significantly altered comparing to each other (Fig. 3.5
and Fig. S1), suggesting that differential epigenetic modifications mainly
occur at distal regulatory regions.
3.2.3 Multivariate data analysis
In order to represent the overall differences from multiple epigenetic modifica-
tions, a single measure is needed to represent the variances between different
datasets. After subtracting each epigenetic mark with the control, the Pear-
son’s correlations between the average values of each epigenetic mark at pro-
moters and enhancers across the samples indicate that there are strong posi-
tive correlations between the repressive marks (H3K27me and H3K9me3) and
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(a) CRC
(b) Colon
Figure 3.5: Histone mark signals around OG, TSG, HKG in CLL and normal
B cells, for the other test cases, see supplementary fig. S1
active marks (H3K4me1, H3K4me3 and H3K27ac), as well as negative corre-
lation between active marks and repressive marks (Fig. 3.6). Co-occurrence
of epigenetic marks is common for multiple activation marks [33]. In addi-
tion, DNA methylation and repressive marks are also negatively correlated,
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as they are often replaced with each other during gene silencing [327,328].
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Figure 3.6: Epigenetic marks in promoter and enhancer regions show strong
correlations with each other
To statistically test the differences between two biological conditions with
each epigenetic mark, I used the epigenetic datasets of embryonic stem cells
(ESC) and compared with their differentiated forms (NPC, MSC, TSC,
MES). The datasets are available in BAM formats. The p-values of the
differential epigenetic signals in both promoter and enhancer regions were
computed with ChIPComp for ChIP-Seq, and BiSeq for WGBS. The com-
bined p-values using Fisher’s method (3.2) are very close to the smallest
p-value in the every comparison (Fig. 3.7). In this situation, combining
p-values from multiple hypothesis testing is not applicable as it may lead
to severe inflation of false positive rates when applied to highly correlated
datasets [329]. Indeed, Fisher’s method makes the assumption of indepen-
dence of the tests, which is not fulfilled here.
X22k ∼ −2
k∑
i=1
ln(pi) (3.2)
(a) MSC (b) NPC (c) TSC (d) MES
Figure 3.7: Combined p-values from histone modifications and DNA methy-
lation
Alternatively, I used a method based on principal component analysis
(PCA) applied to differential signals to represent the overall epigenomic dif-
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ferences. Differential principal component analysis (dPCA) is one of the
methods built on singular value decomposition (SVD) that compares differ-
ential epigenetic signals across multiple histone marks and replicates between
two biological groups [330]. It takes the arithmetic means of each epigenetic
datasets across replicates, and summarizes the observed differences between
the two groups into a matrix D with genomic loci as rows and datasets
as columns. The primary difference between the dPCA and conventional
principal component analysis (PCA) is that it analyses the underlying true
differences by decomposing D into two matrices: D = ∆ + E, where ∆ is
the underlying true differences which I am interested in, and E is the ran-
dom sampling noise. E is calculated as E = σ2Ω, where Ω represents the
diagonal matrix of eigenvalues, and σ2 is estimated from a normal distri-
bution over all loci. Since the number of genomic loci is typically much
larger than the number of epigenetic datasets, SVD can be used to decom-
pose the matrix ∆ = B × V ′, where V ′ is a transposed diagonal matrix, and
B = (β1, β2, · · · , βn) in which βj characterizes the variation in ∆ contributed
by pattern vj.
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Figure 3.8: Characteristics of dPCs. (a) Variances explained by each dPCs.
(b) Correlation of dPCs with gene expression differences in all test cases,
in which dPC1 is positively correlated with gene expression, and dPC2 is
slightly negatively correlated with gene expression.
In these test cases, like the correlation of histone mark differences with
gene expression differences (Fig. 3.4 b), the dPCs still have correlation with
the gene expression differences (Fig. 3.8 b). Among the dPCs, dPC1 ex-
plained ∼ 40% − 100% variances (Fig. 3.8 a), and usually these variances
49
MES MSC NPC TSC
P
C
1
P
C
2
P
C
3
P
C
4
P
C
5
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
Loadings
M
a
rk
CLL CRC GLM PTC
P
C
1
P
C
2
P
C
3
P
C
4
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
-1
.0
-0
.5
0
.0
0
.5
1
.0
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
K27ac
K27me3
K4me1
K4me3
Meth
Loadings
M
a
rk
Figure 3.9: Histone mark contributions to each PC
are mainly contributed by one or two epigenetic marks. Coinciding with the
results from Ji et al., dPC1 appear to be mainly driven by active epigenetic
marks (Fig. 3.9).
Plotting the computed dPC1 values in both promoter and enhancer re-
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gions in the context of the three of the activation marks (H3K27ac, H3K4me1
,H3K4me3) against each biological condition, indicates that dPC1 alone is
able to represent all three marks (Fig. S4 a, b). Other dPCs, taking dPC2
for example, are not representative for the above three marks (Fig. S4 c, d).
3.3 Network representation of promoter-enhancer
relationships
3.3.1 Enhancer-promoter interactions
Both in vivo [331] and in vitro [50], one enhancer can regulate multiple pro-
moters, and one promoters can be under the control of multiple enhancers,
too. Therefore, enhancer-promoter interactions can be presented as a bipar-
tite graph, in which both enhancers and promoters are represented as vertices,
and directed edges link enhancers to their target promoters. In this oriented
graph, the vertices are weighted according to the magnitude of epigenetic
alterations at enhancers and promoters (as measured by the dPCs), and the
edges are weighted according to the probability of such promoter-enhancer
interactions, as will be described in the next section.
3.3.2 Estimating interaction frequencies between en-
hancers and promoters
Enhancers have been found to interact with promoters on the same chro-
mosome (cis) or different chromosomes (trans). It is estimated that most
often, the enhancers are within a limited distance from the target pro-
moter of the same chromosome, a fact which is supported either by polymer
physics [332, 333] or looking at the interaction densities from both experi-
mental data (CD34 and GM12878 [334])(17 blood cells [335]) and in silico
predictions [236,243]. Taking the promoter-enhancer (P-E) interactions from
these observations and predictions, most of the interactions occur within ±1
Mb of the TSS (Fig. 3.10).
Chromatin interaction data in cancer are generally not available to us.
Moreover, besides the dysregulation of histone modifications and DNA methy-
lation, the chromosome loops in cancer cells are believed to be altered [336–
338] comparing to their normal counterparts. I want to develop a method
which can be applied to many different biological contexts, for which, in
general, no experimental interaction data is available. Therefore, I chose to
implement a universal model for interaction probabilities, fitted on a large
set of experimental datasets. The interaction probabilities can be modeled
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Figure 3.10: Interaction density from capture Hi-C and imputation data.
Most of the inferred chromatin interactions occur within ±1Mb range from
the target.
using an exponential function based on P-E distances [236]. For each genomic
region window i ∈ (m,m + 200bp], j ∈ (n, n + 200bp] for a given promoter
position m and enhancer position n, I counted the number of interactions
fij for each interaction (i, j). Afterwards, the probability y was fitted to an
exponential function (3.3).
y ∼ exp(fij, dij) (3.3)
Although physical interactions are generally organized along the whole
chromosome and even trans-chromosomes, functional interactions are more
likely to be limited within topologically associating domains (TADs) [237].
Therefore, I also restricted the promoter and its interacting enhancers to stay
within the same topologically associating domains (TAD). Although TADs
are generally believed to be tissue-specific [339], a test using TADs from
five human cell lines (embryonic stem cell, mesendoderm cell, mesenchymal
stem cell, neural progenitor cell, trophoblast-like cell) provided by Schmitt
et al. [339], has shown that 57% of the promoters have the same contacting
profile in at least 80% of the cell lines.
The likelihoods of enhancer-promoter interaction can be mapped to enhancer-
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promoter distances with a power-law decay function [340]. I estimated con-
sistency of contact frequency profiles from several publicly available cap-
ture Hi-C datasets, including GM12878 (E-MTAB-2323 [334]), 17 blood cells
(EGAS00001001911 [335]), breast cancer (PRJEB23968 [341]), stem cells
(GSE84660 [342]), and colorectal cancer (EGAS00001001085 [343]). During
processing the capture Hi-C data, I required ≥ 10 reads mapped to the other
end of the fragment to infer a reliable interaction.
Discrete binning is used to estimate the parameters in the distance-decay
function. Afterwards, an interpolation method, as implemented by Lajoie
et al. [340] is used. By fitting the average number of interations falling into
each bin against the distances to the promoter to an exponential function, I
obtained exponent values ranged from -8.17 to -1.74 (Fig. 3.11). As expo-
nent coefficients ranging from -1 to -30 display similar performances in later
benchmarking (Fig. 3.14 b), I choose -20 in the following tests.
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Figure 3.11: Probability density functions of several capture Hi-C contact fre-
quencies. y is the probability of the contacts, while x represents the distance
(in Mb) of the interacting region to the promoter.
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3.3.3 Ranking genes using personalized PageRank
I defined a meta-gene as the union of all promoters of the gene and its target-
ing enhancers. I adopted PageRank to summarize the weights of promoters
and connected enhancers into a unique meta-gene score. PageRank is orig-
inally designed in the valuation the importance of web pages [344]. It was
also adopted in bioinformatics in ranking the impact of nodes in metabolic
network [345] or gene ontology network [346]. PageRank yields an impor-
tance score computed through a random walk process, in which a walker
starts from a random vertex, and walks to another connected vertex ran-
domly. This process can be repeated many times. In the end a rank is used
to represent the frequency of visit of each vertex, which is calculated as (3.4).
PR(u) = c
∑
v∈B(u)
PR(v)
Nv
(3.4)
where u represents a vertex, and B(u) are the incoming vertices linked
to u, PR(u) and PR(v) represent ranks of vertices u and v, respectively. Nv
denotes the number of outgoing links from node v.
Depending on the network structure, in a scenario where there are only
incoming links to a vertex, but no outgoing links from that vertex, the walker
will stop at the vertex and the process terminates. To solve this problem, a
reset parameter α is added to allow the walker to restart at any other random
vertex, therefore the final rank becomes (3.5).
PR(u) = (1− α) + α
∑
v∈B(u)
PR(v)
Nv
(3.5)
In practice α is usually set to 0.85, which means the walker has 85%
probability to follow a outgoing link from current vertex, and 15% probability
to hop to a random vertex.
In another scenario specific to my application, the walker has a preference
for some vertices or links over the other ones, and therefore weights of vertices
and edges are introduced. In a ”personalized” PageRank, the rank is also
dependent on the weights of the incoming and outgoing links (3.6).
PR(u) = (1− α) + α
∑
v∈B(u)
PR(v)W in(v,u)W
out
(v,u) (3.6)
where W in(v,u) and W
out
(v,u) are calculated based on the number and weight
of incoming links and outgoing links of vertex v and u.
I used personalized PageRank implemented in igraph [190] to uncover
important epigenetic alterations for a gene by taking into account of the
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regulatory contribution of enhancers. Upon setting the weights of vertices
in the random walk, the promoters or enhancers with more significant epi-
genetic alterations have higher weights, which is represented by the dPCs
previously computed. The dPCs are sorted in decreasing order regardless
of their direction of alteration, as several studies suggest that both up and
down regulation of histone acetylation can contribute to gene activation [347],
as well as hypomethylation and hypermethylation both affect transcription
factor binding, depending on the preferences of transcription factors [176].
I also set edge weights in accordance to the probabilities of chromatin
contacts to ensure that only highly confident enhancers are contributing.
Since the enhancer-promoter network is a directed graph, all the enhancer
scores will eventually be attributed to their interacting promoter. This ensure
that, even in a case where the promoter shows little epigenetic alterations,
the corresponding meta-gene might has a high score due to the contribution
of enhancers. In a next section, I will specifically discuss such cases. In the
end, PageRank returns a vector with the rank scores for all meta-genes, in
which all the genes are ordered according to the cumulative score of their
promoters and associated enhancers.
3.3.4 Benchmarks
In order to validate the outlined procedure, I designed several benchmarking
strategies which I will discuss in the next sections.
Benchmarking using rank lists
The PageRank algorithm sorts the genes into descending order which is in ac-
cordance to the significance of alterations from both promoter and enhancers
(abbreviated as ”PromEnh” rank list). First, I found that the PromEnh rank
list is more relevant to the biological conditions than the rank list derived
from the dPC1 order of only promoters (abbreviated as ”PromOnly” rank
list). In order to show how much improvements I have using the PromEnh
rank list, I compiled a list of 14 ∼ 36 marker genes for each biological test
case (Supplementary table S2 and S3), either selected from comprehensive
literature reviews [348–352], or cancer signature databases, including COS-
MIC [353], Intogen [354], MalaCards [355], etc.
Afterwards, the receiver-operating characteristics (ROC) of cumulative
fraction of markers genes through the ranked list of genes is determined for
assessing the sensitivity and specificity of the ranking. The rank list can be
generated from other dPCs as well. Taking the area under curve (AUC) in
the CLL case as an example, as 70%-80% of the CLL specific marker genes
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are enriched in the top 20% genes of the PromEnh rank list, while for the
PromOnly rank list this value is below 60% (Fig. 3.12 a). This conclusion is
also true for other test cases as well as most of the other dPCs (Fig. 3.12 b).
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Figure 3.12: ROC of CLL and AUC of all test cases. (a) CLL ROC of
PC1-4 using PromEnh rank list (solid lines) and PromOnly rank list (dashed
lines). (b) AUC of dPC1 are plotted as red lines (solid: PromEnh, dashed:
PromOnly), and AUCs from other dPCs are plotted as shaded bands between
the minimum and maximum scores (lightblue: PromEnh, grey: PromOnly).
Benchmarking with transformed vertex weights
So far it is still questionable whether dPC scores are directly related to the
importance of the vertices. Indeed, it could be that, below a certain thresh-
old, small differences in epigenetic signals (and hence small dPC scores) have
no impact on the state of the gene, and should have a zero contribution to
the overall score. Hence, I tested a number of transformations of the raw
dPC scores using functions frequently used in data transformation in artifi-
cial neural networks (Table 3.2) to introduce non-linearity into the vertices
weights (Fig. 3.13 a). Benchmarking with dPC1 using different transfor-
mation functions ended up with similar AUCs (Fig. 3.13 b). Therefore, I
directly used dPCs as the vertex weights to avoid introducing any undesired
side effect.
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Figure 3.13: Transforming functions and AUCs of each function
Table 3.2: Weights transforming functions
Function Equation
Sigmoid f(x) = 1
1+e−x
Logit f(x) = ln( x
1−x)
Exponential f(x) = ex
Inverse exponential f(x) = ln(x)
Identity f(x) = x
Rectified linear unit (ReLU) f(x) = { 0 if i <
n
2
x if i ≥ n
2
Benchmarking with biological evidences
The PromEnh rank lists not only show better coincidence with selected
marker genes comparing to the PromOnly rank lists, but also show better
tissue specificity and are enriched with oncogenes in cancer samples. To show
this, tissue specific genes were retrieved from ARCHS4 Tissues [356] which
is provided with the EnrichR tool [357]. Adjusted p-values from EnrichR
indicate tissue specific enrichment in corresponding test cases. The most
significant term from the enrichment of the top 1000 genes in each PromEnh
rank list shows a remarkable enrichment of corresponding tissues, while the
most significant terms from the top 1000 genes in PromOnly rank list are not
relevant to the corresponding tissues (Table 3.3). Given the fact that super-
enhancers near cell type specific genes often accumulate disease associated
non-coding variants [58, 358], this phenomenon is not a coincidence as it is
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applicable to all the cancer test cases, implying enhancers play a dominant
role in cell type specific regulations.
Table 3.3: Most enriched tissues corresponding to the PromEnh and
PromOnly rank list of test cases
Test case PromEnh tissue Adj. P* PromOnly tissue Adj. P*
CLL CD19+ B cells 6.1e-10 Breast (bulk) 2.3e-23
CRC Small intestine (bulk) 1.5e-16 Spinal cord 2.5e-108
LGG Prefrontal cortex 3.9e-24 Testis (bulk) 0.07
PTC Thyroid (bulk) 2.1e-15 Brain (bulk) 7.0e-33
NPC Spinal cord 3.2e-27 Renal cortex 1.6e-4
MSC Astrocyte 5.7e-37 Fibroblast 3.9e-24
TSC Fibroblast 3.9e-24 Lung (bulk) 6.8e-12
* Adjusted p-value (Benjamini-Hochberg method)
In addition, I found that oncogenes are also highly ranked in the PromEnh
list. I performed Wilcoxon-Mann-Whitney tests on the positions of oncogenes
(OG), tumor suppressor genes (TSG), and housekeeping genes (HKG) in the
PromEnh rank list against a uniformly distributed rank list of the same
length. Comparing to TSG, HKG and random gene sets, OG show a higher
ranking which might be interpreted as a tendency to be under strong epige-
netic regulation in cancer cells. This phenomenon is not observed in the test
cases with normal cells (NPC, MSC, TSC, MES) (Fig. 3.14 a). On the con-
trary, the test cases related to developmental processes show that HKG are
significantly ranked higher when epigenetic regulation is taken into account.
However, all p-values are insignificant when performed using PromOnly rank
list, suggesting that the ranks of OGs and HKGs are mainly explained by
enhancer contribution. Looking at individual genes, BRAF, KRAS are asso-
ciated with stronger enhancer regulation. On the other hand, TP53 is often
associated with weaker enhancer regulation (Fig. 3.15).
Benchmarking with distance based functions
As the promoter-enhancer contact frequencies discussed above, the distances
from the enhancer to the TSS of the promoter determine the likelihood of
promoter-enhancer interaction, and the effect can be modeled with power-
law decay. I tested a series of exponent values in the decay function from
which the edge weights were calculated as (3.7).
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(a) Wilcoxon tests of OG,TSG,HKG ranks
comparing to uniformly distributed rank.
OGs in cancer are significantly ranked
higher in PromEnh rank list, whereas they
are not significant in developmental test
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Figure 3.14: Rank list benchmarking.
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Figure 3.15: Ranking positions of well known genes in PromEnh and
PromOnly list. Genes on the bottom-left corner are ranked low in both
lists, while genes on the top-right corner are ranked high in both lists. Genes
on the top-left corner are only ranked high in PromOnly list, and genes on
bottom-right corner are only ranked high in PromEnh list
wi = exp(m× di + β) (3.7)
where m is the coefficient I am estimating, and di indicates the distance
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(in Mb) between the enhancer to the promoter, and β is the intercept from
the fitted function. Therefore, setting m = 0 implies that all enhancers
have the same weights regardless of their distances to the promoter. Also
calculated from (3.7), when m ≈ −3912, the weight of an enhancer with a
distance of 1kb to the promoter drops by 98% comparing to an enhancer at
the same genomic location of the promoter, which essentially means that the
contributions of enhancers in the PageRank are negligible in this scenario,
and the AUCs are very close to ranking promoters only. Therefore, a coeffi-
cient m ∈ (−10,−30) seems suitable in maximizing the AUC and matching
with the experimental estimation (Fig. 3.14 b), without exaggerating the
contribution from enhancers.
Robustness of the gene ranking under random perturbations
To validate that the contributions from enhancers are not an artifact, I used
degree-preserving random perturbations, which rewires the endpoints of the
edges with a 50% probability randomly to another vertex in a graph. The
randomization can be realized using a rewired promoter-enhancer network
in PageRank. During the test with 100 permutations of different rewired
network structures, I used the same marker genes as in the benchmarking,
and the AUCs with randomly assigned enhancers dropped 10%-20% for most
of the test cases (Fig. 3.16). Nevertheless, the AUCs from rank list including
random enhancers still outperformed the rank list using promoter only. I
assume that the reason is because the rewiring did not change the number
of enhancers that a gene might have. Therefore, the ranking of cancer and
development marker genes will benefit from enhancers no matter which en-
hancers were linked to them, but the ranks of the other genes are disordered
and hence the AUCs are lower.
3.4 Network representation of gene relation-
ships
3.4.1 Network construction
Considering the top ranked genes could be artifacts, the relatively high
ranked genes with known biological functions are more appealing to me, even
though they may not be the highest in the rank list. The most common way
to perform functional annotation of a rank list of genes is by doing a gene-
set enrichment analysis (GSEA). But applying GSEA on high-throughput
epigenetic data is still debatable, as severe biases towards genes related to
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Figure 3.16: AUCs of PromEnh rank list from randomized promoter-
enhancer interactions. The grey band regions indicate the quantile ranges
from benchmarking each with 100 different rewired promoter-enhancer net-
works, whereas the red lines show the AUCs with the original promoter-
enhancer interactions from PromEnh (solid line) and PromOnly (dashed line)
rank lists.
development and differentiation have been mistakenly reported in a wide
range of DNA methylation studies [359]. Therefore, I performed a network
analysis over the rank lists. The rank lists are examined in a context of biolog-
ical networks such as protein-protein interaction networks, and significantly
altered genes might appear clustered together in accordance with their biolog-
ical functions. The context can be known signaling pathways, co-expression,
or protein-protein interactions etc. Here I chose Human Protein Reference
Database (HPRD) as the reference network [360]. HPRD contains manually
curated scientific information of most human proteins related to their bi-
ological functions, including protein-protein interactions, post-translational
modifications, enzyme-substrate relationships and disease associations.
I used igraph to find communities from HPRD via short random walks.
Multiple edges and self-loops are removed. I limited the genes of interests
to a percentage of the top ranked genes, and the edge weights are com-
puted as the average rank of the two connected genes. The edge directions
are ignored in HPRD in random walk. Using the highly ranked genes as
”seeds”, the random walk clustering returns several dense subnetworks. The
genes in the subnetworks are non-overlapping. This method recovered more
cancer-related genes due to the fact they have more interacting partners
than non-cancer genes [361–363]. In a test I took out the top fifteen largest
subnetworks, generated with thresholds of the top 10%-50% ranked genes.
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The genes enriched in the subnetworks exhibit higher oncogene frequencies
comparing to the frequencies in the PromEnh rank list. As the frequencies
of oncogenes dropped along with the PromEnh rank list, the oncogene fre-
quencies stayed stable in the extracted subnetworks, implying the network
clustering succeeded in selecting the biological meaningful genes in cancer
(Fig. 3.17).
Figure 3.17: Frequencies of oncogenes in the network clustering. The solid
lines represent frequencies of oncogenes in the enriched subnetworks built
from top 10%-50% genes of PromEnh rank list, while the dashed lines indicate
the frequencies of oncogenes in the top 10%-50% of the PromEnh rank list.
Identifying modules and pathways in diseases
Functional analysis of the subnetworks obtained as described previously un-
covers a few interesting pathways for my test cases by analyzing the genes
in these subnetworks with EnrichR. Many of them are general biological
processes and signaling pathways, yet some of them show specific functions
related to the cancer types. In table 3.4 I listed a few of the subnetworks
ranked in descending order of the sum of vertex weights.
In the center of the subnetworks reside the hub regulators, which are
linked by many genes with epigenetic alterations. For example, SMAD2 and
SMAD3 expression have been shown to be regulated by histone modifications
of their promoters [383]. In the following part, I will highlight two cancer
specific pathways.
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Table 3.4: Top ranked specific functions from network clustering
Case Biological functions Hub regulators* Adj. P**
CLL Toll-like receptor signaling pathway TLR1, TLR4 [364] 1.0e-7
CRC HIF-1 signaling pathway [365,366] EPAS1 [367] 7.6e-4
LGG TGF-β signaling pathway [368] SMADs 1.8e-6
LGG Notch signaling pathway [350] NOTCH2 [369] 7.5e-14
PTC PI3K-Akt signaling pathway [370] FGFs [371,372] 4.0e-9
MSC Osteoblast signaling pathway PTH [373] 1.0e-3
NPC Hedgehog signaling pathway [374] ZIC3 [375] 7.6e-9
NPC Axon guidance [376] Ephrins [377,378] 2.8e-18
TSC MAPK cascade [379,380] MAPK1 [381] 6.5e-16
TSC EPO receptor signaling pathway [382] PTPRC 0.015
* Hub regulator indicates a gene surrounded by several significantly altered
genes.
** Adjusted P-value (Benjamini-Hochberg method)
Chronic lymphocytic leukemia
Toll-like receptors (TLR) are iconic markers in both normal and malignant
B-cells. They mediate innate immune response via pattern recognition of
antigens. TLR4 and TLR9 gene expression were lower in CLL than in healthy
individuals [364, 384], while TLR2 was highly expressed in both CLL [384]
and acute myeloid leukemia (AML) [385]. Accordingly, I observed both hy-
peracetylation and hypoacetylation of the TLR genes and their neighboring
enhancers in my test case (Fig. 3.18), which may lead to their differential
expression in the end. The toll-like receptor signaling pathway is only re-
covered from network analysis, and GSEA did not identify this pathway,
which indicates network analysis is powerful in enriching pathways with few
members.
Colorectal cancer
Colorectal cancer (CRC) is a malignant cancer affecting colon or rectum,
and accounts for ∼ 9% of all cancer deaths [386]. Network clustering of
the epigenetic alterations of promoters and enhancers suggests that HIF-1
pathway is the top candidate. HIF-2α overexpression is frequent in multiple
cancers, and is associated with poor prognosis [365,366]. I further identified
EGLN3 and HIF-2α (EPAS1), whose scores are mainly contributed from
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Figure 3.18: Toll-like receptor signaling pathway is associated with strong
epigenetic alterations in CLL. Here I attached a screenshot from crl program
to illustrate the analysis procedure: a. Network browser showing enriched
pathways, corresponding genes are highlighted in red on selection from the
drop list; b. Clicking on a gene of interest will direct to a web page showing
neighboring enhancers, as well as their dPCs in colored ranges; c. By clicking
the promoter ID of the gene, a heatmap-like epigenome browser appears,
showing the intensities from each epigenetic mark between tests and controls;
d. Clicking the enhancer IDs will allow users to read additional information
from GeneCards [384], as well as their predicted targets; Clicking a track
in the epigenome browser will redirect users to WashU Epigenome Browser
[260], showing a more detailed view of epigenetic signals for that point of
genomic region.
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epigenetic alterations of nearby enhancers (GH14I033835 and GH02I046346,
respectively). These genes are also differentially expressed between CRC and
normal cells. Baba et al. also confirmed EPAS1 overexpression in a cohort of
731 colorectal cancers [387], and Yoshimura et al. proved EPAS1 is associated
with high grade colorectal cancer in 88 patients [367]. The enriched network
not only revealed EGLN3 and EPAS1, but also included HIF-1α, MYC and
MAX as potential regulatory factors.
3.4.2 Discovery of novel cancer related enhancers
Besides studying the pathways enriched for epigenetic alterations, I also ana-
lyzed the highly altered enhancers associated with certain genes of interests.
PAX5 and MYC are two candidate genes discovered from their consistent
high ranking in PromEnh list from all the test cases (Fig. 3.15). As their
ranking in the PromOnly are not high, it suggests PAX5 and MYC are
extensively regulated by enhancers. PAX5 is a key TF involved in B-cell
development, and its promoters have no significant epigenetic alterations in
CLL. However, taking the nearby enhancers into consideration, this gene is
associated with several hyperacetylated and hypomethylated enhancers, one
of which located 330 kilobases (kb) upstream of the PAX5 TSS has been
found as extensively mutated in CLL [388] (Fig. 3.19). Deletion of this en-
hancer resulted in a 40% reduction in the expression of PAX5 and chromatin
interaction of this enhancer and PAX5 have been proven from chromosome
conformation capture sequencing (4C-Seq) analysis [388].
By analyzing the significantly altered oncogenes across cancer cohorts, I
identified a large enhancer region, also referred to as super-enhancer, regu-
lating MYC [58]. The enhancers are located around 20 ∼ 200kb downstream
of MYC, overlapping with the long non-coding (lncRNA) PVT1. PVT1 has
been found to positively influence MYC expression [389–391], and is also con-
sidered as an oncogene. Cho et al. found that PVT1 competes with MYC for
access to this super enhancer, and disruption of the PVT1 promoter leads to
greater enhancer activity of MYC as well as an increase in expression [392].
The enrichments in H3K27ac and H3K4me1 signals of this enhancer have
been observed in all cancer test cases (Fig. 3.20). Also, cis-interactions were
detected using an orthogonal conformation capture technique [393]. The Hi-
C profiles from the most similar available tissues or cell lines of each cancer
type (K562, Huvec, GM12878 [232], Hippocampus [339] were used in uphold-
ing the chromatin interactions in CLL, CRC, PTC, LGG, respectively) are
visualized using Hi-C data Browser [394] and placed above the genomic view.
Another enhancer in the vicinity of MYC, known as the ”Blood ENhancer
Cluster” (BENC) [395], has also been recognized from increased H3K27ac
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levels in CLL (Fig. 3.20 c) and LGG (Fig. 3.20 g).
3.4.3 Development of an R package for integrative epi-
genetics analysis
I have developed an R package named ”crl ” incorporating the differential
analysis steps described in this chapter. Crl features a variety of tools for
visualizing network clusters and epigenetic alterations, which is crucial for
both hypothesis generation and detection of potential artifacts. Comparing
with other network presentation tools, such as Cytoscape [396], the display of
networks in crl is fully adapted to highlight differential epigenetic alterations
from both the PromEnh and PromOnly rank list (Fig. 3.18 a), allowing one
to inspect principal components of epigenetic marks for the gene of inter-
ests, and further navigate to a snapshot of the genomic regions of epigenetic
tracks from each biological replicates, while existing tools, such as the WashU
Epigenome Browser [260], load very slowly when visualizing a large amount
of epigenetic tracks (Fig. 3.18 c).
An alpha version of this tools is available in GitHub for inspecting the
enriched pathways for the cancer and development test cases. It can be
accessed from http://qwang-big.github.io/crl-web/ .
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Figure 3.19: A known PAX5 enhancer in CLL exhibits hyperacetylation and
hypomethylation.
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(a) K562 (b) Huvec
(c) CLL (d) CRC
Figure 3.20: Continued on next page.
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(e) Hippocampus (f) GM12878
(g) LGG (h) PTC
Figure 3.20: A super enhancer near MYC exhibits hyperacetylation in can-
cers. The proposed super enhancer regions are bordered with black solid
lines on the genome tracks, wherein the cancer samples are marked with red
strips, and normal samples are marked with blue strips. Solid red lines indi-
cate the chromatin interaction between MYC and this enhancer in Hi-C, and
dashed lines indicate the interactions between MYC and another superen-
hancer ”BENC”.
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Chapter 4
Discussion
In this thesis I presented several approaches to incorporate and combine
multiple epigenetic data types, from multiple regulatory loci with complex
relationships, to describe the underlying regulatory mechanisms in cell devel-
opment and cancer. Generally, these approaches perform either quantitative
or qualitative analysis of epigenetic modifications. Qualitative analyses are
efficient in solving simple problems, such as definition and classification of
regulatory regions, but become incompetence when complex relationships
and multiple dependencies are involved. Quantitative analyses, on the other
hand, are powerful when it comes to intensities and probabilistic levels of
data integration, yet comprehensive benchmarking is essential in defining
and validating the modeling assumptions. Both approaches are covered in
this thesis, and their applicable scenarios and efficiencies are discussed in the
applications of a variety of cancer and development test cases.
4.1 Descriptive analysis of the epigenetic mod-
ifications
In first main topic, I focused on the descriptive analysis of the epigenetic mod-
ifications. I analyzed enriched regions (peaks) from the ChIP-Seq of histone
modifications in a particular cancer type, namely glioblastoma multiforme
(GBM). As the presence of the peaks is the only feature in descriptive analy-
sis, the accuracy of peak calling is crucial in making conclusions. Therefore,
various settings with several peak callers have been tested, and they presented
similar outputs at sharp peak regions (H3K4me1, H3K4me3, H3K27ac), but
vary largely in the broad peaks (H3K9me3, H3K27me3, H3K36me3). Bal-
ancing the trade-off between sensitivity and specificity, I tend to use the same
peak caller for all analyses, as the GBM classification with SICER led to a
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remarkable agreement with other subtyping approaches, such as 450k methy-
lation array and WGBS. I also inferred regulatory elements directly from the
positions and combinations of these peaks, and I distinguished active/poised
promoters and enhancers. The common and specific regulatory elements in
GBMs and normal brain tissues reflect the distinct possible mechanisms in
tumorigenesis and progression by means of both pathway analyses (Fig. 2.6)
and subtype specific signature genes (Fig. 2.7)
4.1.1 Chromatin states
In order to comprehensively depict all the combinations of epigenetic modi-
fications for GBMs, I employed the widely used tool ChromHMM. There are
several options in building ChromHMM, in both the binarization step and
modeling step. Firstly, I tested binarized signals from peak callers, and from
the built-in Poisson model of ChromHMM. Binarization using peak callers
has been previously applied on building a 38 states model including 6 his-
tone marks and 13 transcription factors by Predeus et al. [397], wherein they
used SICER peaks with parameters for calling narrow peaks (200bp window
size, 200bp gap size). However, owing to the broadness of epigenetic marks,
they still need to adjust the gap size (600bp) for H3K27me3 and H3K36me3.
Also, as I investigated the benchmarking of ChromHMM in GBMs, the bi-
narized signals from peak calls with the same parameters failed to address
the actual boundaries of either active or repressed regions, causing overesti-
mation or underestimation of several types of chromatin states (Fig. 2.10).
On the other hand, ChromHMM applies independent cut-off for each mark
using a Poisson distribution, which makes it more suitable to use in the bi-
narization step. In the modeling step, regarding the number of states and
marks, I either directly used the Roadmap 18-states model, or learned a new
HMM from the binarized data. Although I have tested a variety of num-
bers of states and epigenetic marks (even including DNA methylation), the
model varies largely across different samples and subtypes. In addition, the
models contain a large redundancy in some chromatin states, either caused
by sequencing biases in ChIP-Seq data, or the underlying heterogeneity of
GBM epigenomes. In the end, I used the Roadmap 18-states model for the
downstream analyses, to make the result comparable to previous Roadmap
analyses.
4.1.2 Subtype specific epigenetic patterns
In the end of the GBM study, I discussed the potential use of deep neural
network in subtype specific epigenetic patterns classification. Deep learning
71
is one of the most popular modern machine learning approaches. Comparing
to other traditional classification methods, deep learning greatly reduces the
need for feature engineering, which is one of the most time-consuming parts of
machine learning practice. Specifically, comparing to the k-means method I
used in classifying subtype specific epigenetic modification patterns, it avoids
choosing the optimum number of clusters, yet it guarantees discovery of
the patterns used in training. The disadvantage is that some patterns are
rare, while neural networks require a large amount of data to train. This
shortcoming can be compensated by making use of the synthetic data. From
the test cases with one of the histone mark, the approach allowed me to
identify the desired patterns of subtype active promoters, and a literature
mining suggests they are highly relevant to the specific phenotypes, which
makes it feasible to apply this approach with even more epigenetic marks
and complex patterns.
4.2 Quantitative analysis of the epigenetic mod-
ifications
The second main topic of the thesis is on the quantitative analysis of the epi-
genetic modifications. To achieve this I analyzed the epigenetic contrasts
between two biological conditions. Several evidences suggested that the
magnitude of epigenetic differences correlates with gene expression levels.
Nonetheless, epigenetic comparison is not equivalent to differential gene ex-
pression analysis. As illustrated in the ”epigenetic priming” section (3.1),
differential gene expression is the possibly delayed outcome of differential
epigenetic modifications, which highlights the importance of differential epi-
genetic analysis. In order to analyze the underlying variances of multiple
epigenetic modifications, the epigenetic signal intensities of eight human cells
(four cancer and four normal cells) and five stem cells (ESC and four ESC-
derived cells) are generated based on the sequencing densities of pre-defined
promoter and enhancer regions. As I was using the annotated enhancers
from all the tissues [311], enhancers were further filtered with H3K4me1 to
eliminate the unspecific enhancer regions.
4.2.1 Data validity and reliability
In the beginning, I started from analyzing the data quality by testing multiple
correlations between epigenetic modification and global gene expression level,
gene expression differences of two groups, and correlations between multiple
epigenetic marks. These verified my assumptions that epigenetic intensities
72
are important in epigenetic regulation. Epigenetic modification are generally
categorized into two types, which are active and repressive. The epigenetic
marks of the same type are highly positively correlated and negatively corre-
lated with the other type. Therefore, a straightforward combination of mul-
tiple hypothesis testing of multiple epigenetic marks is not feasible as high
rate of false positives may be introduced due to the redundancy between
marks [329]. However, the highly correlated structure of epigenetic marks
is preferable in a dimensionality reduction approach, making it possible to
represent these marks with a few principal components using dPCA [330].
4.2.2 Dimensionality reduction
Many challenges arise in dimensional reduction step. In the first place, data
normalization is challenging due to the different background noises between
epigenetic marks. So far I use normalization methods developed in RNA-Seq
analyses, which does not make use of the ChIP-Seq control. In my current
approach, the signal levels are estimated from uniform background noise dis-
tribution. However many studies have shown that the influences from chro-
matin accessibility [398], GC content [185,186], copy number variation [187],
may cause biases in the noise model. Furthermore, dPCA explicitly use nor-
mal distribution to estimate signal-to-noise ratio, which requires stabilization
via variance transformations.
Also, for the follow-up analyses of promoters and enhancers ranking with
multiple epigenetic marks, linear approximations are used in nearly all levels
of data integration. Specifically, as I want to factorize the high-dimensional
epigenetic data, the dPCA linearly maps the data points to a low-dimensional
latent space. Because I only used PC1 for analyzing the differences from
multiple epigenetic marks, although the low-dimension representations of
some of the datasets were satisfying (Fig. 3.8 a), there is not always a
linear function that can explain the relationship between genomic datasets
[242]. Therefore, non-linear dimensional reduction techniques, such as t-
stochastic neighbor embedding (t-SNE) and autoencoder may be expected
to have greater potential in complex models.
4.2.3 Incorporating non-coding elements
There is a great necessity in incorporating distal non-coding regulatory ele-
ments into differential epigenetic comparisons. For example, although H3K4me1
is a sign of activate chromatin, the correlation of H3K4me1 inside promot-
ers with gene expression is fairly weak (Fig. 3.4). In fact H3K4me1 signals
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extend to±5kb region of the TSS, and positively associated with gene expres-
sion [399]. Therefore, a method is required in order to capture distal epige-
netic modifications in the functional non-coding regions, primarily enhancer
elements. As the region around promoter may contain many enhancers, and
in turn one enhancer can distally interact with many promoters [400]. The
relationships are not sufficiently captured in one-to-one or many-to-one pre-
sentation. Accordingly, graph data structure is an ideal solution for depicting
such relationships, as it also enables mapping enhancer-promoter regulations
into directed links. Although there are numerous algorithms in picking up
useful information from a graph, PageRank seems the most appropriate in
solving such problem. At the time of writing, PageRank has been applied in
prioritizing candidate genes from protein-protein interaction [345, 401] and
microarray [346] data, but was never used in interpreting biological contri-
bution from non-coding elements and epigenetic data.
As the magnitude of epigenetic alterations at promoters and enhancers
can be interpreted as vertex weight, and enhancer-promoter interaction con-
fidence can be interpreted as edge weight, a ”personalized” PageRank is more
suitable in modeling such complex regulatory relationships than conventional
PageRank. Nonetheless, since edge weights are solely estimated from P-E dis-
tances, it is still arguable that false positive rate of chromatin interactions is
uniformly distributed along the genomic region or across samples [402]. Al-
though a universal distance decay function for generating enhancer-promoter
probabilities is practicable in my approach, one can expect employing more
specific contact profiles (from Hi-C or ChIA-PET) would result in more re-
alistic interaction probabilities.
4.2.4 Benchmarking
To test whether the epigenetically significantly altered candidates from previ-
ous analyses make biological sense, I performed a number of tests on the gene
ordering from PageRank, which measures the overall alteration from both en-
hancer and promoter epigenetic modifications. The benchmarking was done
using four cancer and three developmental test cases, each compared with
corresponding normal tissues or embryonic stem cells. Benchmarking on dif-
ferent principal components, different signature genes sets, a variety of edge
weights and node weights generating functions, as well as the permutations
of promoter-enhancer network structures, all these analyses supported my
hypothesis, that the enhancers are the most important elements in cell dif-
ferentiation and cancer progression. Besides finding novel signature genes
specific to epigenetic regulation in tumorigenesis, the enhancers identified
from this approach would also be good candidates for functional studies of
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enhancers in carcinogenesis.
4.3 Integrative analysis tools
Encapsulating the above quantitative analysis into an R package provides
great usability for biologists to test the epigenetic cohorts in their studies. It
is more desirable if one can examine the epigenetic alteration within the con-
text of reference database such as HPRD or STRING [403]. The web applica-
tions of crl allows to trace back these layers of information which are hidden
during dimension reduction. With these test cases, I highlighted a few path-
ways and enhancers of interests, which coincide with previous descriptions
of PAX5 and MYC enhancers. Despite the fact that high MYC expression
is common in cancers, coding mutation of MYC is not prevalent in cancers.
MYC expression is considered to be precisely controlled through epigenetic
mechanisms. These tools also generated many enhancer/oncogene/pathway
candidates of oncological interests for the biologists to investigate.
4.4 Outlook
In conclusion, the approaches presented in the thesis provide novel solu-
tions to study the genome-wide epigenetic cohort studies in development
and cancer, as well as hypothesizing to the discovery of epigenetic hotspots
for experiment. Epigenetic mechanisms can be proposed from comprehen-
sive analyses of regulatory elements specific to cancer subtypes, integration of
multiple epigenetic datasets, inference from biological networks, etc., which
highlight various abnormalities in cancer progression. Given that epigenome
alterations are reversible upon treatment with epigenetic drugs, it is advan-
tageous over gene editing in cancer treatment. Therefore, computational
aided precise oncology will shed a new light on both cancer diagnosis and
epigenetic therapies.
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Table S1: Oncogenes, tumor suppressor genes, and housekeeping genes used
in the analysis
Oncogenes
ABL1 ABL2 AKT1 AKT2 ATF1 BCL11A
BCL2 BCL3 BCL6 BCR BRAF CARD11
CBLB CBLC CCND1 CCND2 CCND3 CDX2
CTNNB1 DDB2 DDIT3 DDX6 DEK EGFR
ELK4 ERBB2 ETV4 ETV6 EWSR1 FEV
FGFR1 FGFR1OP FGFR2 FUS GOLGA5 GOPC
HMGA1 HMGA2 HRAS IRF4 JUN KIT
KMT2A KRAS LCK LMO2 MAF MAFB
MAML2 MDM2 MECOM MET MITF MPL
MYB MYC MYCL MYCN NCOA4 NFKB2
NRAS NTRK1 NUP214 PAX8 PDGFB PIK3CA
PIM1 PLAG1 PPARG PTPN11 RAF1 REL
RET ROS1 SMO SS18 TCL1A TET2
TFG TLX1 TPR USP6
Tumor suppressor genes
APC ARHGEF12 ATM BCL11B BLM BMPR1A
BRCA1 BRCA2 CARS CBFA2T3 CDH1 CDH11
CDK6 CDKN2C CEBPA CHEK2 CREB1 CREBBP
CYLD DDX5 EXT1 EXT2 FBXW7 FH
FLT3 FOXP1 GPC3 IDH1 IL2 JAK2
MAP2K4 MDM4 MEN1 MLH1 MSH2 NF1
NF2 NOTCH1 NPM1 NR4A3 NUP98 PALB2
PML PTEN RB1 RUNX1 SDHB SDHD
SMARCA4 SMARCB1 SOCS1 STK11 SUFU SUZ12
SYK TCF3 TNFAIP3 TP53 TSC1 TSC2
VHL WRN WT1
Housekeeping genes
C1orf43 CHMP2A EMC7 GPI PSMB2 PSMB4
RAB7A REEP5 SNRPD3 VCP VPS29
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Table S2: Stem cell differentiation marker genes
Neural Progenitor Cells (NPC)
ABCG2 [404] ASCL1 [405] BMI1 [406] CD133 [407]
CXCR4 [349] FOXA2 [408,409] FOXO1 [410] FZD9 [411]
GAP43 [412,413] GFAP [414,415] GLUT1 [416] HES1 [417,418]
MAP2 [409] MSI1 [419] NES [420] NEUROD1 [421]
NFIX [422] NOTCH1 [423,424] NTN1 [425] OTX2 [426]
PAX3 [427,428] PAX5 [428] PAX6 [409,428,429] PAX7 [428]
PAX8 [428] S100B [430] SMARCA4 [431] SOX1 [429,432]
SOX11 [433] SOX2 [434,435] SOX3 [436] SOX4 [433]
SOX9 [437] SYP [409] TCF12 [438] VIM [439]
Mesenchymal Stem Cells (MSC)
ALCAM [440] ANPEP [441] CD44 [441,442] CD70 [348]
DLK1 [443,444] ENG [348,442] ETV1 [445] ETV5 [445]
FOXP1 [445] GATA4 [446] GATA6 [445] HMGA2 [445]
ITGA4 [447] ITGB1 [442] MYOD1 [446] NANOG [441,448]
NCAM1 [441] NT5E [441] OCT4 [448] PDGFRA [448,449]
POU5F1 [450,451] PPARG [446] RUNX2 [441,446] SIM2 [445]
SOX11 [445] SOX2 [450–452] SOX4 [453] SOX9 [441,446]
SPARC [441,454] THY1 [348,442] VIM [455]
Trophoblast Stem Cells (TSC)
ARID3A [456] BMP4 [457] CD9 [458] CDH1 [459]
CDX1 [460] CDX2 [457,460–462] CGA [460,463,464] CGB [458,463,464]
ELF5 [459,465] EOMES [457,459,463,466] ESRRB [459] ETS2 [457]
FGF4 [467] FGFR2 [457,459,468] FURIN [457] GATA2 [460,464]
GATA3 [457] GCM1 [464] HAND1 [460] ID2 [469,470]
IGFBP3 [464] KRT7 [458,464] MMP9 [464] MSX2 [464,471]
SMARCA4 [466] SOX2 [459,464] TEAD4 [472] TFAP2C [457]
TFAP2C [457,459,466]
107
Table S3: Cancer marker genes
Chronic Lymphocytic Leukemia (CLL)
ARID1A (2.41 [388,473]) ATM (9 [474], 4.14 [473,475])
BCOR (1.72 [476]) BIRC3 (2.5 [477], 19.7 [478])
BRAF (3.7 [479], 2.8 [388,480]) CHD2 (5.3 [481], 4.8 [479,482])
CXCR4 (OE [483–486]) DDX3X (1.03 [473], 2.4 [474], 1.72 [487])
EGR2 (3.8 [479,488]) FBXW7 (1.03 [473], 2.5 [474,489])
IRF4 (1.5 [388,490]) MYD88 (2.2 [477], 4 [491], 8 [474], 5.17 [473,489])
PAX5 [388] NOTCH1 (3.1 [473], 4 [474], 8 [477], 11.3 [488,489,492])
SAMHD1 (11 [493,494]) SF3B1 (11.2 [477], 15 [474], 7.93 [473,474,489])
SYK (OE [495–497]) TP53 (10.4 [477], 15 [474], 7.1 [489], 8.62 [473])
XPO1 (2.76 [473], 3.4 [489]) ZAP70 (OE [498,499])
Lower Grade Glioma (LGG)
ARID1A (11 [500], 5.92 [473]) ARID1B (11 [500], 2.37 [473])
ATRX (42.6 [501,502]) BRAF (15 [503] , 1.85 [504,505])
CIC (20.12 [502]) EGFR (OE [506], A [507], 23.22 [504], 4.14 [473])
FUBP1 (10.65 [508]) IDH1 (77.51 [509,510])
IDH2 (3.55 [510]) NF1 (5.92 [473,504,509])
NOTCH1 (7.69 [473] , OE [511]) PIK3CA (6.51 [473], 10.03 [504,509,512,513])
PDGFRA [514,515] PIK3R1 (5.92 [473,504,509,516])
PTEN (4.14 [473], 30.34 [504,509]) RB1 (1.78 [473,504,509])
SOX9 (OE [517,518]) TCF12 (3.55 [519])
TP53 (50.89 [473], 30.61 [504,509])
Colorectal Cancer (CRC)
APC (79.04 [520] ) BRAF (16 [521], 4.7 [522], 3 [520,523])
EGFR (12-22 [524–526] ) KRAS (40 [522], 43 [520,521,523,527])
FBXW7 (10 [520] ) PIK3CA (14.5 [522], 15 [520,521,523,528])
SMAD2 (3.4 [520,529] ) PTEN (14 [521], 4 [520,522,523,530,531])
SMAD3 (4.3 [520,529] ) SMAD4 (8.6 [520,529,532])
SOX9 (3.49 [473], 4 [520,533]) TCF7L2 (9.17 [473,534], 12 [520])
TGFBR2 (3.49 [473], 2 [520,535]) TP53 (59 [520])
Papillary Thyroid Cancer (PTC)
AKT1 (15 [536] ) ALK (10 [536] )
ARID1B (1 [537] [538] ) BRAF (35.8 [539], 56.52 [473] )
CTNNB1 (25 [536] ) EGFR (5 [536] )
EIF1AX (1.5 [537,540] ) HRAS (20-40 [536,541] )
KMT2C (1 [537] [538] ) KRAS (20-40 [536,541] )
NDUFA13 (15 [536] ) NRAS (20-40 [536], 8.07 [473,541] )
PIK3CA (1–2 [536] ) PTEN (4.8 [536,542] )
TG (2.7 [537] ) TP53 (25 [536] )
ZFHX3 (1.7 [537] )
Numbers in the brackets represent the expression (OE stands for overexpression)
or mutation (A: amplification, number: percentage of mutation rate) of the gene.
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(a) PTC
(b) Thyroid
(c) CLL
Figure S1: Continued on next page.
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(d) B cell
(e) LGG
(f) Normal brain
Figure S1: Histone mark signals around oncogenes (OG), tumor suppressor
genes (TSG), housekeeping genes (HKG)
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(a) H3K27ac MACS2 (b) H3K27ac MACS2
broad
(c) H3K27ac SICER
(d) H3K27me3
MACS2
(e) H3K27me3
MACS2 broad
(f) H3K27me3 SICER
(g) H3K36me3
MACS2
(h) H3K36me3
MACS2 broad
(i) H3K36me3 SICER
(j) H3K4me1 MACS2 (k) H3K4me1 MACS2
broad
(l) H3K4me1 SICER
(m) H3K4me3
MACS2
(n) H3K4me3 MACS2
broad
(o) H3K4me3 SICER
Figure S2: Continued on next page.
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(p) H3K9me3 MACS2 (q) H3K9me3 MACS2
broad
(r) H3K9me3 SICER
Figure S2: Correlation heatmap using all bound sites for each histone mark.
(a) IDH vs. MES (b) IDH vs. RTK I (c) IDH vs. RTK II
(d) MES vs. RTK I (e) MES vs. RTK II (f) RTK I vs. RTK II
(g) Normal vs. MES (h) Normal vs. RTK I (i) Normal vs. RTK II
Figure S3: States transitions shown in percentage between each subtypes
and normal brain
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(a)
(b)
Figure S4: Continued on the next page.
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(c)
(d)
Figure S4: dPC1 and dPC2 for three histone marks. The mean log intensities
for every genomic locus in group one and group two from six test cases are
plotted against each other, and the nodes are colored according to their dPC
scales.
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